By 2:30 a.m., a CT scan showed a massive brain hemorrhage. Surgery to evacuate the blood and remove a section of skull — a hemicraniectomy, so the swelling brain has somewhere to go besides down through the base of the skull, which is the direction that kills you — began at 3:15 a.m. and ended at 5:30.

Lucy’s Oura ring later revealed when her physiology had fallen off a cliff: roughly 9 a.m. the previous morning. More than nineteen hours had passed between the bleed and the end of the operation.

Ackman writes that he was told afterward the standard teaching is not to operate on a large hemorrhage that far out — that beyond about five hours the damage is presumed done, and the likeliest purchase is a few months in a nursing home before pneumonia finishes it. [1]

I want to be careful with that number, because it is the hinge of the whole story. It is not a formal guideline you will find in a consensus document. It is the kind of thing an exhausted surgeon says at 3 a.m. — a rule of thumb distilled from a great many patients who did not do well. And rules of thumb are not cruelty or laziness. They exist because we must act under uncertainty, and a rule is better than a coin.

But a rule built from averages tells you what usually happens. It does not tell you what is possible. And no average has ever met the specific patient on the gurney.

They operated anyway. She lived.

What “she lived” actually looked like

Lucy spent weeks in a coma. When she woke, she could not breathe on her own, walk, speak, or see. Her pupils no longer reacted to light.

The blindness did not come from the blood. During those nineteen hours, prolonged hypoperfusion starved her optic nerves and her retinal ganglion cells — the neurons that carry vision to the brain. By eight weeks the nerves showed frank atrophy. At three months, nothing had improved. [2]

Six months later the picture was different, if still unfinished. Cognition had returned; she understands everything, including, unbearably, her own circumstance. She can walk more than a hundred steps with help. Sounds, vowels, consonants, and the first fragments of speech are appearing. [3]

Vision has not.

Her father tells her the same thing every day: make a little progress today. Daily progress compounds.

That is a hedge fund manager’s sentence, and it is also, precisely, the physiology of neurorehabilitation. The brain does not heal the way a cut heals. It rewires. Surviving circuits take over abandoned jobs, slowly, through relentless repetition, and the curve is not linear — it is exponential in the way compound interest is exponential, which is to say invisible for a long time and then suddenly not.

I have watched families lose faith in month three because they were measuring in days. The ones who make it measure in years.

The ancient organelle

Here is where the story becomes something I did not expect to be writing about in 2026.

Imaging showed something that mattered enormously: the retinal nerve fiber layer and the ganglion cells had not entirely vanished, and some visual signal was still, faintly, reaching the visual cortex. [2]

The cells were not dead. They were starving.

Retinal ganglion cells are among the most metabolically greedy neurons in the body. They run almost entirely on oxidative phosphorylation. They are, functionally, mitochondria with axons attached. When a cell that hungry is injured, the first thing to fail is its power plant.

So the Mount Sinai team asked a question that is either obvious or insane depending on which decade you trained in: what if we gave the cells new batteries?

Under FDA emergency expanded access, a team led by rehabilitation neuroscientist David Putrino and neurosurgeon Christopher Kellner isolated mitochondria from a small piece of Lucy’s own leg muscle and injected them into the vitreous fluid of each eye, twenty-four hours apart. [4]

Mitochondria are the cell’s power plants — descendants of free-living bacteria that took up residence inside our single-celled ancestors more than a billion years ago. Damaged neurons can take up healthy ones from outside. In rodents, mitochondria delivered into the vitreous after optic-nerve injury are absorbed by exactly these cells and improve their survival. [2]

This was the first time it had been attempted in a human eye. It had already been done in the human heart and, more recently, the human brain — but for the eye there was no dose, no safety profile, and no delivery experience at all. [2] The report is a preprint, posted August 10, not yet peer reviewed. [5] The authors were explicit that they were testing safety, not claiming a cure. “We can’t prove efficacy at all, nor are we trying to,” Putrino said.

Neither eye developed inflammation. Pupillary reactivity — absent across all forty-five pre-treatment readings over seventy-one days — returned in each eye within days. [6] The responses held above pre-transplant levels, and on low-vision assessment she was perceiving shapes and shadows in her left eye. [4]

Then it faded. The left eye recorded its last normal response on day 11; the right kept producing sporadic normal responses until day 39. Her measured visual acuity did not change. [6]

Separately, writing publicly, her father has said the family has seen a sustained though weaker benefit since the first injection, and that they are working toward giving the injections more frequently. [1] That is his account, not the paper’s, and the two are worth keeping straight.

The honest part

I am going to be blunt, because this is the section where most people writing about this story will fail you.

This is one patient. There was no control group. There was no microscopy and no biopsy — no direct evidence that the transplanted mitochondria ever actually entered her retinal ganglion cells rather than sitting inert in the vitreous. [6] The authors say plainly that a single case cannot establish causation, and the report remains preliminary pending peer review. [5] An independent mitochondrial biologist in Basel called the procedure relatively safe while noting it does not confirm any therapeutic effect. [4]

Safety, not cure. That is the correct reading, and anyone who tells you otherwise is selling something.

Now let me tell you why the fade is the most interesting part rather than the disappointing part.

The fade is exactly what the bench work predicts. Donor mitochondria are internalized by recipient cells within hours and largely cleared over the following days. In transplanted cardiomyocytes, respiration and ATP production climb by day two and drift back toward baseline afterward. [7] In retinal ganglion precursor cells, donor mitochondria are inside by three hours and already declining by twenty-four. [8]

A transient effect that decays over weeks is therefore not a refuted hypothesis. It is a dose-duration problem. The batteries worked and then ran down — a different and far more tractable problem than batteries that never worked at all.

And the field has already begun solving it. One group more than tripled how long donor mitochondria survived inside retinal cells simply by priming those cells with moderate oxidative stress beforehand. [8] In April, Botond Roska’s group in Basel published a system in Nature they call MitoCatch, using engineered protein binders to aim donor mitochondria at chosen cell types. It delivered mitochondria into neurons and retinal, cardiac, endothelial, and immune cells, where the transplanted organelles stayed functional — moving, fusing, dividing. Optic nerve atrophy is named among its intended targets. [9] [10]

Targeting. Retention. Redosing. Those are engineering problems, and medicine is very good at engineering problems once it decides a thing is worth engineering.

Why a cardiologist is telling you this

Because it did not start in the eye. It started in the heart.

The first human mitochondrial transplants were performed in Boston, in children, during cardiac surgery — myocardium stunned after ischemia and reperfusion. [11] Same logic exactly. The muscle is not dead, it is de-powered; restore the power plant and you may recover tissue the textbook had already written off.

I have spent twenty-five years standing in front of hearts the numbers said were finished. Ejection fraction of fifteen. Scar on the MRI. Guidelines pointing gently toward hospice. And I have watched enough of those hearts come back — with time, with relentless therapy, with a patient who refused to be a statistic — to have developed a permanent professional suspicion of the word irreversible.

Irreversible usually means we do not currently know how yet. Those are not the same sentence. We say the first one because it is shorter.

From one life to an institute

Ackman had told Lucy’s doctors something simple at the beginning: give her the best care possible, he would invest unlimited resources, and whatever they learned would be shared with everyone.

On August 19 he announced that he and his wife, the designer Neri Oxman, are donating roughly $400 million in Pershing Square stock — ten million shares — to anchor a new institute, with a second gift of similar or potentially greater size still to come. [3] The Ackman Oxman Institute will occupy 3.4 acres on Manhattan’s West Side: a newly acquired 400,000-square-foot biotech building on West End Avenue bought at a steep discount, an adjoining 130,000-square-foot facility currently used as studio space by Saturday Night Live, and neighboring parcels — potentially 680,000 square feet in all, [12] a laboratory footprint larger than Rockefeller University, overlooking the Hudson.

The design is patient-centric rather than paper-centric: a nonprofit with commercial instincts and its own venture arm, so that devices, drugs, rehabilitation protocols, brain-computer interfaces, nutrition, hyperbaric oxygen, and longevity work move from idea to patient as fast as possible. No silos. No exclusive university monopoly. Mount Sinai is a partner, not the only one.

The board includes the inventor Dean Kamen, Regeneron co-founder and chief scientific officer George Yancopoulos, the Nobel-winning biochemist James Rothman, the neuroscientist Bernardo Sabatini, Chris Kellner — the neurosurgeon who led Lucy’s care — Pershing Square Foundation CEO Olivia Flatto, Oxman, and Ackman himself. A CEO has been identified and is expected to be announced by October, with searches underway for a chief scientific officer, a chief AI and technology officer, and other senior leadership. [3]

Five years ago, Ackman says, the same idea failed on arithmetic: Manhattan real estate was too expensive and top scientists could not be pried away from universities. He argues both variables have moved — the real estate came available at a discount, and campus politics and funding cuts have made academia less attractive. [3] He names antisemitism among the reasons.

You may agree with that diagnosis or you may not. I would ask you to notice the structure beneath it, because the structure is the actual news. A father looked at the specific machinery that failed his daughter — not the surgeons, who were superb, but the slowness of the pipeline between an idea and a patient — and bought that machinery a replacement.

Most grief turns inward. This one turned into steel and square footage.

The calling

I want to say something now that Ackman does not say himself, and I want to be clear that it is mine and not his. He wrote his letter as a businessman and a father. He allowed himself exactly one theological word — divine intervention — and left it there, which is roughly the ratio I hear from surgeons at four in the morning.

But I recognize the shape of what he did, because I was raised inside a tradition that has a name for it.

There is a line in the Talmud that anyone who saves a single life is regarded as having saved an entire world. It gets quoted so often that it has gone soft, so let me sharpen it back into what it actually claims: the world is not a category. The world is one person. There is no such thing as saving humanity in general.

Everything in this story flows from that. A neurosurgeon operated on a patient the average said not to touch. A rehabilitation team built a protocol for one woman. A cardiac surgeon’s technique, an ophthalmologist, and a mitochondrial biologist converged on one pair of eyes, under emergency authorization, for one patient, with no expectation of proving anything to anyone.

And because they did it for one, there is now a delivery route, a dose, a safety profile, and a published record. The next hundred people with starving optic nerves inherit something that did not exist in February.

That is how it always goes. The general good is a byproduct of somebody’s particular love.

There is a second idea our tradition insists on, and it is the harder one. Suffering is not explained. It is not made meaningful by being explained. It is made meaningful by what you build on top of it. Tikkun olam is not a feeling — it is a construction project. You are not asked to understand why the world broke. You are asked to repair the part of it you are standing next to.

Ackman was standing next to a gurney in a Queens trauma hospital at two in the morning. He is now building 680,000 square feet on the Hudson.

I don’t know how Lucy’s story ends. Neither does her father, and he says so plainly — he thinks it will take years. But I know its shape. Cognition first. Then the walking. Then the vowels. Somewhere out ahead, God willing, the light.

His own words are the wager, and I would put money on them: if you are going to have a devastating brain injury, this is the best moment in human history for it to happen.

He closed his letter by turning an old line: the mind is a terrible thing to waste.

So is a nineteen-hour window that somebody decided to open anyway.

Blessings.

Afshine Emrani, MD, FACC is a board-certified cardiologist and Assistant Clinical Professor of Medicine at the UCLA David Geffen School of Medicine.

References

1. Bill Ackman, public letter posted to X, August 19, 2026. — x.com/BillAckman

2. Putrino D, Kellner C, McCully J, et al. First intravitreal mitochondrial transplantation for bilateral vision loss. Research Square preprint, posted August 10, 2026. Not peer reviewed. — researchsquare.com/article/rs-10622019/v1 · doi:10.21203/rs.3.rs-10622019/v1

3. Bill Ackman’s $400 million brain institute was inspired by his daughter. Fortune, August 20, 2026. — fortune.com

4. Patient’s own mitochondria injected into eyes in attempt to restore vision. Nature news, August 2026. — nature.com

5. First mitochondrial transplantation into the human eye. World Mitochondria Society, August 2026. — wms-site.com

6. World first: mitochondria from a woman’s leg were injected into her eyes. ScienceAlert, August 2026. — sciencealert.com

7. Ali Pour P, Kenney MC, Kheradvar A. Bioenergetics consequences of mitochondrial transplantation in cardiomyocytes. J Am Heart Assoc. 2020;9(7):e014501. — doi.org/10.1161/JAHA.119.014501

8. Aharoni-Simon M, Ben-Yaakov K, Sharvit-Bader M, et al. Oxidative stress facilitates exogenous mitochondria internalization and survival in retinal ganglion precursor-like cells. Sci Rep. 2022;12:5122. — doi.org/10.1038/s41598-022-08747-3

9. Ayupov T, Moreno-Juan V, Curtoni S, et al. Cell-type-targeted mitochondrial transplantation rescues cell degeneration. Nature. Published online April 15, 2026. — nature.com · doi:10.1038/s41586-026-10391-0

10. “MitoCatch” delivers healthy mitochondria to diseased cells. University of Basel / Institute of Molecular and Clinical Ophthalmology Basel, April 15, 2026. — unibas.ch

11. Emani SM, Piekarski BL, Harrild D, del Nido PJ, McCully JD. Autologous mitochondrial transplantation for dysfunction after ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2017;154(1):286–289. — doi.org/10.1016/j.jtcvs.2017.02.018

12. After his daughter’s brain hemorrhage, Bill Ackman commits $400 million to brain research. CTech, August 2026. — calcalistech.com

You wake up heavy. You reach for the second espresso before 11. You bloat by mid-afternoon, fog over by four, and drag yourself to dinner running on caffeine and willpower. And we’ve all agreed to call this one word:

Aging.

I want to tell you something I’ve learned in over two decades as a cardiologist, watching what actually moves the needle inside the human body:

It’s usually not aging. It’s friction.

Not the slow, dignified wear of years — but a daily, invisible, fixable irritation happening at the border of your gut, your blood vessels, and your cells. Remove the friction, and the “old” feeling lifts faster than almost anyone expects. Often in weeks.

Here’s how it works, and exactly what to do about it for the next 28 days.

The Border You’ve Never Thought About

The lining of your gut — the wall between the food you eat and the blood that feeds every organ — is a single cell thick. One layer. That’s the entire membrane standing between the outside world and your bloodstream.

When that lining is healthy, it’s a sealed, selective border. It lets nutrients through and keeps everything else out.

But modern life is hard on that border. Ultra-processed food, refined sugar, chronic stress, and alcohol wear down the seams between those cells. The tight junctions loosen. And when they do, fragments of bacteria — endotoxins called lipopolysaccharides (LPS) — slip out of the gut and into the blood, where they were never meant to be.

Your immune system does exactly what it’s built to do. It sees foreign invaders in the bloodstream and sounds the alarm. Not a loud, obvious alarm — a low, constant, smoldering one.

  Processed food · sugar · stress · alcohol
                    │
                    ▼
        Gut lining loosens  ──▶  Endotoxins (LPS) leak into blood
                                          │
                                          ▼
        Low-grade inflammation  ──▶  Mitochondria run dirty
                                          │
                                          ▼
              Fatigue · fog · stiffness · that "old" feeling

That smoldering inflammation is the part almost no one connects the dots on. It reaches your blood vessels. It reaches your mitochondria — the tiny power plants inside every cell that turn food and oxygen into energy. And when your mitochondria are spending their day fighting inflammatory background noise, they can’t do their real job: making you feel alive.

So you’re not “just tired.” Your cellular power plants are running dirty, distracted, and starved — while the fire drill never quite ends.

Here’s the hopeful part: this is one of the most reversible systems in the entire body. Seal the border. Quiet the fire. Feed the power plants. Your body does the rest — and it does it fast.

The Plan: 28 Days, Three Moves

No calorie counting. No weighing food. No white-knuckle deprivation. Just three moves, repeated: rebuild the plate, remove the noise, and (optionally) fuel the repair.

Move 1 — Rebuild the Plate

Every real meal follows one simple architecture. Not grams — proportions.

½ your plate: colorful, fibrous vegetables. Arugula, kale, spinach, broccoli, Brussels sprouts, asparagus, zucchini. This isn’t about vitamins alone. The fiber in these plants feeds your good bacteria, which in turn produce butyrate — the exact compound your body uses to seal and repair the gut lining. You are quite literally eating the raw material that rebuilds the border.

A palm-sized portion: clean, complete protein. Pasture-raised eggs, wild salmon, grass-fed beef, poultry, or tempeh. Protein delivers the specific amino acids — glutamine, glycine, proline — that patch the gut wall and hold onto lean muscle.

A thumb or two: intelligent fats. Extra-virgin olive oil (be generous), avocado, walnuts, macadamias, chia, tahini. These steady your blood sugar, slow digestion, and keep energy flat instead of spiky.

That’s it. Build every plate that way and the rest takes care of itself.

Move 2 — Remove the Noise

For 28 days, you’re pulling out the four biggest sources of gut friction so the lining can actually heal. Not forever. Just long enough to see who you are without them.

• Ultra-processed food and refined sugar — the fuel for the exact bacteria you’re trying to starve.

• Alcohol — zero, for the full 28 days. This is the non-negotiable one. Alcohol pries the gut open and wrecks the deep, restorative stage of sleep. Nothing else on this list moves the needle as fast.

• Gluten and conventional dairy — the two most common quiet irritants. Pull them for the month; many people are stunned by what lifts.

• Liquid sugar — juices, sweet lattes, soda. The fastest sugar hit your liver can get, and the least worth it.

You are not giving these up forever. You’re clearing the stage so you can finally hear the signal.

Move 3 — Fuel the Repair (Optional Accelerant)

Food does the heavy lifting. Supplements are the accelerant — helpful, not mandatory. Before starting any of these, run the list past your own physician — especially if you take medication for your heart, blood pressure, or blood thinning, or if you’re pregnant. Some of these interact with real drugs, and this article is education, not a prescription for your specific body.

To rebuild the gut lining:

• L-Glutamine — 5g, empty stomach, first thing. The primary fuel for the cells that line your gut.

• Spore-based probiotic + prebiotic fiber (acacia or PHGG) — strains tough enough to survive stomach acid and colonize where it counts.

• Zinc Carnosine — with dinner. Studied for adhering to irritated gut tissue and reinforcing the seams.

To wake up the mitochondria:

• GlyNAC (glycine + N-acetylcysteine) — replenishes glutathione, your cells’ master antioxidant.

• Urolithin A — a postbiotic being studied for triggering mitophagy, your cells’ cleanup crew for worn-out mitochondria.

• CoQ10 / Ubiquinol — direct support for the energy chain in heart and brain tissue.

• Omega-3s (EPA/DHA) — the body’s own “resolve the inflammation” signal.

• Creatine — not just for muscle; it reloads energy in brain and nerve tissue too.

• Magnesium (glycinate or L-threonate) — before bed. Relaxes the nervous system and deepens sleep.

Your Daily Blueprint

┌──────────────────────────────────────────────────────────────┐
│                  THE 28-DAY DAILY RHYTHM                      │
├──────────────────────────────────────────────────────────────┤
│ 7:00 AM   Big glass of water + pinch of sea salt             │
│           L-Glutamine + GlyNAC (empty stomach)               │
│                                                              │
│ 8:30 AM   MEAL 1 — 3 eggs · sautéed greens · ½ avocado       │
│           Probiotic · Omega-3 · CoQ10 · Urolithin A          │
│                                                              │
│ 1:00 PM   MEAL 2 — wild salmon over arugula, walnuts, EVOO   │
│           Creatine in water                                  │
│           → then a 3–4 hour no-snack window                  │
│                                                              │
│ 6:30 PM   MEAL 3 — grass-fed steak · charred asparagus · EVOO│
│           Zinc Carnosine                                     │
│                                                              │
│ 9:30 PM   Magnesium                                          │
│           → 12–14 hour overnight fast begins                 │
└──────────────────────────────────────────────────────────────┘

Three real meals. Clean gaps between them. A long, unbroken night for your body to do its repair work while you sleep. Simple enough to actually follow — which is the only kind of plan that ever works.

What the 28 Days Actually Feel Like

Days 1–7 — The De-Flaming. Water weight drops. The 3 p.m. sugar crash starts to fade. The first week is your body exhaling.

Days 8–14 — The Quiet. Bloating disappears. Digestion goes silent — the good kind of silent. The afternoon energy cliff you’d accepted as normal simply… isn’t there one day.

Days 15–28 — The Turn. This is where people get surprised. Deeper sleep. Waking up before the alarm and actually wanting to. Sharper thinking. Steadier stamina. Not a different body — your body, running clean.

Individual results vary, of course. Some people feel it in a week; some need the full month. But the direction is remarkably consistent once the friction is gone.

The Challenge

Your body has an extraordinary, underestimated capacity to repair itself. It’s not asking for a miracle. It’s asking you to stop fighting it — to pull out the friction and hand it the raw materials it’s been missing.

Give it a clean slate for 28 days. See who you are on the other side.

Drop your start date in the comments. Or restack this for the person you know who’s running on caffeine, willpower, and burnout — and calling it aging.

They deserve to know it might be something else.

Blessings,

Afshine “Ash” Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

🏅 Castle-Connolly Nationwide Top Doctor (since 2008) 🌟 Los Angeles Magazine Super Doctor (since 2010) 🇺🇸 LA Style Magazine, Top 100 Doctors in America (2024)

📬 Subscribe: substack.com/@afshineemrani 📚 My books: Amazon Author Profile

This article is for education, not individual medical advice. Talk with your own doctor before changing your diet or starting supplements — especially if you take prescription medication or have a chronic condition.

The loop was built to save you from a short threat — a predator, a fall, a fight. It fires, it protects you, it stands down. But modern life never sends the all-clear. So the loop keeps running. And what it produces is not “feeling stressed.” It’s something quieter and more expensive: a gradual rewrite of your sleep, your metabolism, your immune system, your arteries, and the very circuits your brain uses to turn danger off.

This is a field guide to what that rewrite actually does — and how to reverse it with actions that reach the two cables most people skip.

The system that never clocks out

Two branches fire when something feels like a threat.

The fast branch is the sympathetic-adrenal surge: adrenaline, noradrenaline, heart rate up, blood shunted to muscle, digestion paused. This takes seconds.

The slow branch is the HPA axis. The hypothalamus releases CRH, the pituitary releases ACTH, the adrenals release cortisol. This takes minutes to hours. Cortisol frees fuel, sharpens alertness — and then, if the threat ends, it should fall so repair can begin.

That last clause is the whole game.

Chronic load doesn’t just “raise cortisol.” It breaks the off switch.

Under sustained pressure, the feedback receptors in your hippocampus and prefrontal cortex desensitize. The daily cortisol slope flattens: weak mornings, wired evenings, 3 a.m. wake-ups. Later the axis can blunt entirely. You don’t feel like a cortisol fountain. You feel tired-but-wired, then just tired. Sympathetic tone stays high. Heart-rate variability falls. Inflammatory signaling drifts up even as some immune defenses weaken.

That cumulative wear has a name: allostatic load. It is the bill for staying switched on.

What the rewrite actually does

Brain. Under long glucocorticoid exposure, memory circuits in the hippocampus prune their branches. The amygdala gets louder. Prefrontal braking gets weaker. Rumination isn’t a character flaw — it’s the same threat circuit firing with no body to run.

Sleep. Cortisol is a wake hormone. Evening leftover plus sympathetic residual fragments your deep sleep. Sleep loss then raises the next day’s reactivity. The loop feeds itself.

Metabolism. Fuel gets biased toward glucose and visceral storage. Insulin gets sloppy. Sex hormones and thyroid output get deprioritized. Midsection fat isn’t only calories — it’s a local cortisol amplifier.

Vessels. Psychosocial load tracks with cardiovascular risk in observational studies. The plausible paths: pressure load, endothelial strain, clotting tendency, low-grade inflammation. Stress is not “the cause of every heart attack.” It is part of the milieu that makes injury and clot more likely.

Immunity. Acute cortisol damps inflammation. Chronic dysregulation does the opposite over time — more inflammatory chatter, worse recovery after the hard month, and the classic collapse on the first day of vacation.

None of this requires a dramatic life. Unfinished decisions, rumination, late-night light, isolation, and a gut that keeps sending threat packets are more than enough.

The missing off-switch: your vagus nerve

The vagus is the main parasympathetic highway. Here’s the fact that reframes everything: roughly 80% of its fibers run up — from body to brain, not the other way around.

It reports on gut stretch, inflammation, heart rhythm, and whether the world feels safe enough to digest. When vagal tone is high, your heart rate varies beautifully beat to beat, inflammation quiets, and the HPA axis can finally stand down. When tone is low, the body stays “on call.”

You don’t “find your vagus.” You train the conditions that recruit it. Ranked by mechanism and evidence — not by how photogenic they look:

1. Resonance-frequency breathing (the strongest at-home lever). Breathe at roughly 4.5–7 breaths per minute — your personal resonance frequency, often near six — so your blood-pressure waves and heart rhythm lock into phase. Baroreceptors fire. Brainstem nuclei recruit vagal outflow. Meta-analyses show meaningful drops in anxiety and gains in HRV after weeks of practice. Five to twenty minutes daily beats an occasional hour. No sensor? Inhale 4, exhale 6–8. Sit or lie down, nose in, slow out, ten minutes after waking or before bed.

2. Cold on the face — not a personality contest. Cold water on the forehead and eyes triggers the mammalian diving reflex through the trigeminal nerve, which pulls in vagal bradycardia. A bowl of cold water or a 20–30 second face dunk is closer to the physiology than a heroic ice bath. Full-body plunges are a stressor — useful for some, destabilizing if you’re already flattened, sleep-broken, or cardiac-risk. Face first. Short. Then breathe.

3. Voice: hum, sing, gargle. The vagus innervates the larynx and pharynx. Vibration plus a long exhale is the point — not volume. Sixty to 180 seconds of a comfortable hum after a hard meeting is enough. The evidence is thinner than for paced breathing, but the risk is near zero. Use it as a spike-breaker, not a religion.

4. Exercise that finishes the sprint. A walk, a set of stairs, a shake-out after conflict completes the motor pattern the alarm started. Moderate aerobic and Zone 2 work raise HRV over weeks. Redlining daily on an already-loaded axis is more threat, not more tone.

5. Social safety. A calm voice, eye contact, physical presence — these are direct ventral-vagal inputs. Isolation isn’t neutral; it’s a biological amplifier of load. Schedule people the way you schedule training.

6. Devices: taVNS and implanted VNS. Implanted cervical VNS is a real medical therapy for specific epilepsy, treatment-resistant depression, and some inflammatory conditions — not a wellness gadget. Transcutaneous auricular VNS (taVNS) stimulates the ear’s auricular branch and shows shifts toward parasympathetic dominance with mixed psychophysiology. Parameters matter enormously: site, frequency, duration, sham quality. Consumer neck clips routinely outrun the data. If you try one, treat it as an experiment with published settings. Pacemakers, active implants, or certain ear conditions — ask a clinician first.

7. Mostly hype. Endless “vagus hacks,” ice-bath identity, and gadgets promising to reset your nervous system in four minutes. Breathing, sleep, movement, and people still do most of the work.

A practical stack for most bodies: resonance breathing daily, a face-cold or cool-shower finish a few times a week, a hum when the spike hits, a walk after meals, protected sleep. Add taVNS only when the basics are already boringly consistent.

The other cable: the gut

The gut is not a side quest. It is a second stress organ, and it talks to your brain four ways at once.

• Neural. Vagal afferents and spinal pain fibers carry stretch, toxin, and immune signals up to the brainstem, then to the hypothalamus and limbic system. Your enteric nervous system can run digestion without you — but it still reports upstairs.

• Immune. When the barrier leaks, fragments like LPS and peptidoglycan meet pattern-recognition receptors. Cytokines (IL-6, TNF-α, IL-1β) then activate the HPA axis and microglia.

• Endocrine. Cortisol and CRF change motility, mucus, and permeability. Enteroendocrine cells release serotonin, GLP-1, and PYY — signals that also hit vagal endings.

• Metabolic. Microbial short-chain fatty acids (butyrate, acetate, propionate), tryptophan metabolites, and bile-acid products shape inflammation, barrier tightness, and even the daily timing of your cortisol.

Here’s the part that makes chronic stress so sticky — it’s a two-way street:

Stress → CRF and sympathetic drive scramble motility, thin the mucus layer, loosen tight junctions. Microbiome diversity drops. Opportunists rise. Those microbes and their fragments then push the HPA axis back on. Germ-free animals show exaggerated stress-hormone responses to restraint — and colonizing them early can reset the set point. Newer work shows the microbiota even helps keep your daily cortisol rhythm on schedule. Wipe the microbes, and both the brain’s stress clock and the daily glucocorticoid wave drift.

That is one reason nights feel wrong when the gut is wrong.

So “fix stress and the stomach follows” and “fix the gut and anxiety vanishes” are both half-true. They’re the same circuit.

What to do with that:

• Feed the barrier, not a brand. Plant fiber, resistant starch, and fermented foods give microbes the substrate for butyrate — the fuel of your colon cells and a signal that tightens junctions. If fiber wrecks you at first, go slow. That’s adaptation, not a moral failing.

• Cut the daily hits that open the gate. Alcohol, ultra-processed meals, all-day grazing, and late heavy dinners keep insulin and CRF elevated the same night the HPA is trying to fall. A 3-hour buffer before bed isn’t dogma — it’s fewer glucose swings demanding a nocturnal cortisol mop-up.

• Use microbes as a tool, not a miracle. Human probiotic evidence is strain-specific and modest. A multi-strain product for 8 weeks is a reasonable experiment if bloating, urgency, or post-meal brain fog are part of your stress picture. Stool tests as identity are mostly theater.

• Recruit the vagus from below. Slow eating, warmth, not working through lunch, a walk after the meal — all afferent inputs. The same nerve that slows the heart tells the brain the gut is not under siege.

The reversal protocol

Pills without safety, completion, and rhythm are expensive coping. Do this in order.

Daily, non-negotiable

• Light. Outside light in your eyes within 30 minutes of waking — no sunglasses for that window. The HPA clock takes its cue from your retina, not your intentions.

• Water, then coffee. Early cortisol is already climbing. Stacking caffeine on an empty, dry system is a reliable morning-anxiety machine. Cut caffeine by noon if sleep is thin.

• Ten minutes of resonance breathing. Longer exhale. Same time each day. This is your vagal set.

• Walk after the main meal. No phone. Glucose stays quieter; the vagus stays in the conversation.

• Close one loop. One decision, one message, one unfinished task. Background tabs are cortisol.

• Dark, cool, phone in another room. Cortisol is a wake signal. Light and the “is something incoming?” pulse keep the night sympathetic.

When the spike hits

Hum for 60 seconds. Or splash cold on your face. Or take the stairs. Complete the cycle the alarm started — then one long exhale.

Weekly

Real social contact on the calendar. One environment audit: who leaves you smaller? Heat plus a brief cool if you tolerate it. Skip heroic cold if your sleep collapses afterward.

Food that serves the axis

Protein early if mornings shake. Plants and fermented foods if the gut can take them. Last calories earlier. Enough carbohydrate around training so the axis isn’t scavenging. Not a religion of macros — just fewer emergency pulses.

Supplements — force multipliers, not the plan

Start one at a time. Check thyroid, pregnancy, autoimmune disease, and medications first.

How you’ll know the hardware is changing

Don’t worship a single cortisol number. Watch a cluster over four to eight weeks:

• Sleep latency and 3 a.m. wake count

• Morning energy vs. afternoon crash

• Resting heart rate and HRV trend

• How fast you come down after a spike

• Bloating, urgency, post-meal fog

• Patience and empathy — chronic load shrinks the social brain

Rhythm and caffeine changes can move sleep in days. Body composition and “I feel like myself again” take 6–12 weeks if the load built over years. That’s appropriate. You’re retraining a clock, a nerve, and an ecosystem — not flipping a switch.

The sentence to keep

Your body is not broken. It is still running a program that used to keep you alive. The program cannot tell a notification from a predator, or a restless gut from a wound.

You do not out-think a loop that lives in the brainstem, the vagus, the immune system, and the microbes that set your daily cortisol wave. You give the loop proof: light at dawn, a long exhale, a finished sprint, a meal that doesn’t keep the night on call, people who are safe, and fewer hours rehearsing lions that are not in the room.

Do the boring pieces first. Use cold, voice, and devices as accessories. Feed the barrier. Measure more than mood.

Give it thirty honest days.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

But something is smoldering.

It is. I can tell you what it is, where it’s burning, and — this is the part almost no one talks about — why it flares worst in the morning and how to put it out. Most of the fix is free, and you can start tomorrow before breakfast.

Two kinds of fire

Inflammation isn’t the villain. It’s a rescue crew.

When you cut your finger or catch a virus, your body lights a fast, hot fire: swelling, redness, immune cells flooding the scene. The fire does its job, the injury heals, the fire goes out. That’s acute inflammation, and you’d die without it.

The problem is the other fire. The one that never goes out.

When inflammation fails to resolve, it drops down to a low, constant smolder — too quiet to feel, hot enough to do damage year after year. This is chronic inflammation, and it is the common root beneath most of the diseases we fear: heart disease, type 2 diabetes, many cancers, fatty liver, Alzheimer’s, and autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease.

Here’s the key idea that changes everything: it’s all one fire. Your gut, your gums, your belly fat, your stress, your terrible sleep — they aren’t separate problems. They’re all feeding the same flame through the same wiring. Fix one, you turn down the whole system. Ignore them, and they amplify each other.

The smoke alarm that never resets

Inside your immune cells sits a molecular smoke alarm called the NLRP3 inflammasome.

Its job is to detect danger — bacterial fragments, cellular stress, damaged mitochondria — and sound the alarm by releasing inflammatory signals. In a healthy body, it blares when there’s a real fire and goes silent when the danger passes.

In a chronically inflamed body, it never fully resets. It stays primed — finger on the trigger, quietly leaking inflammatory signals into your bloodstream day and night. Those signals are what corrode your arteries, ache in your joints, and cloud your brain.

So the real question isn’t “how do I fight inflammation?” It’s: why did the alarm stop turning itself off?

The part no one told you: your body runs on a clock

Here’s where it gets remarkable.

You have a molecular night manager. Its name is REV-ERB, and one of its jobs is to walk through your immune cells on a schedule and tell that smoke alarm to stand down. It literally presses down on the genes that build the alarm. Alongside its partner BMAL1, it gates your inflammation to a daily rhythm — quieter at certain hours, allowed to rise at others.

This is why so many inflammatory conditions flare in the morning. That stiffness isn’t random. It’s the tail end of your body’s overnight immune schedule.

And here’s the catch. That night manager only clocks in if your body knows what time it is.

Late-night screens. A bedtime that drifts by hours. Midnight snacks. Shift work. Darkness in the morning and light at night. Every one of these tells your internal clock that time itself has become meaningless — and the night manager stops making his rounds. The alarm never gets the stand-down order. It stays primed. The fire keeps smoldering.

This isn’t theory. Shift workers — people whose clocks are chronically scrambled — carry measurably higher inflammation and higher rates of heart disease, autoimmune illness, and cognitive decline. Their bodies have lost track of what time it is, and their immune systems pay the bill.

A quick, honest word on the “miracle” pill

You may have seen biohackers online buying a research chemical called SR9009 — a drug that artificially switches on that night manager. In mice, it does impressive things: calms colitis, reduces liver scarring, quiets the inflamed brain.

Let me be direct, because this is where people get hurt. SR9009 has never completed a single human clinical trial. Its absorption in people is poor and poorly understood. It’s banned in competitive sport. It is a laboratory tool, not a medicine.

Meanwhile, the free version already lives in your day: morning sunlight, a steady bedtime, and meals eaten while the sun is up do the same job — switch on the night manager, reset the alarm — with decades of human evidence behind them and zero risk.

The people paying for the mouse drug are chasing what your morning walk gives away for free.

How to put out the fire

You interrupt this network in four places: the gut, the mouth, the cell, and the clock. Here’s the protocol I give my own patients.

1. Fix the clock first — it’s the cheapest and most overlooked. Get sunlight in your eyes within an hour of waking (outside, no sunglasses, even on a cloudy day). Keep a consistent 7–9 hour sleep window, same times weekdays and weekends. Dim your lights and screens after sunset. This single category re-hires your night manager.

2. Eat with the sun. Keep your food inside a daytime window — try to finish eating 2–3 hours before bed. Late-night eating confuses the same clock that controls your inflammation. When you eat matters nearly as much as what you eat.

3. Eat like the Mediterranean. Vegetables, berries, extra-virgin olive oil, fatty fish, nuts, legumes. Aim for 30+ grams of fiber a day — fiber feeds the gut bacteria that seal your intestinal lining and keep inflammatory triggers out of your blood. Cut the ultra-processed food, added sugar, and frequent alcohol; these tear that lining open.

4. Treat your mouth as part of your heart. Gum disease leaks bacteria straight into your bloodstream and feeds the exact same fire — and it measurably raises heart and diabetes risk. Brush twice daily, clean between your teeth every single day, and see your dentist every six months. This is cardiovascular medicine.

5. Move to make medicine. 150 minutes of moderate activity plus two strength sessions a week. Muscle releases anti-inflammatory signals when you use it — and exercise helps re-synchronize your clock.

6. Add only after the foundation is built. Once the above are in place, 1–2 g of EPA/DHA (fish oil) and vitamin D (if you’re deficient) are reasonable, evidence-supported adjuncts. They work with a healthy foundation, not instead of one.

The one thing to remember

You don’t need to be perfect. You need to be consistent.

Morning light. A reasonable eating window. Floss every night. The same bedtime. Do these, and you retrain the immune system that was built to protect you — so it stops mistaking your own body for the enemy.

The fire you can’t feel is real. But the switch that turns it off is already inside you.

It just needs to know what time it is.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

The egg that became you was not made by your mother. It was made inside her — while she herself was still a fetus, unfinished, curled and floating inside your grandmother.

Here is how that happens. A female builds her entire lifetime supply of eggs before she takes a single breath. By around 20 weeks in the womb she already holds six to seven million of them — more than she will ever have again. Then the number begins to collapse, before she is even born. By delivery day she is down to one or two million. It keeps falling every day she is alive. Out of that whole vast reserve, only about 400 will ever be released.

So run the sequence backward and watch what it forces you to admit. At one exact moment, your grandmother’s body contained your mother. And your mother — still a fetus, still months from her first cry — already contained the single cell that would one day become you.

Three generations. One body. Stacked inside each other like a set of nested doors, and only the outermost one had any idea it was happening.

Now do the arithmetic, because this is where a curiosity turns uncanny. A woman born in 1976 grew from an egg that formed around 1946 — three decades before her own birthday, inside a body that had not yet been born itself. A piece of her was quietly present at a moment she would spend her whole life filing under ancient history.

Two honest caveats, because the truth holds up better without exaggeration. First: an egg carries only half your genetic code, so the cell waiting inside your grandmother was half of you, not all of you. Second: a handful of mouse studies have hinted that females might manufacture a few new eggs in adulthood — but the finding is disputed, and nobody is rewriting the textbooks over it.

What is not in dispute is the timing. Your mother never made that egg. She was assembled around it. It was already there, waiting, while her body was still building itself.

The engines were switched on before you existed

Then there is the part with no caveat at all.

The mitochondria — the microscopic engines inside every one of your cells, the machinery that turns food into usable energy, the reason you are warm and moving and reading this — come only from the egg. Only from the mother. Never from the father, not one of them.

Which means the mitochondria running you at this exact second were switched on inside your grandmother’s body, decades before you existed. And if you are a woman with a daughter, the engines powering her entire life were assembled inside you — while you carried her, without the faintest idea what you were building.

Now pull that thread as far as it goes. Your mitochondria came from your mother. Hers from her mother. Hers from her mother. An unbroken chain, mother to daughter to daughter, that never once passes through a man and never once skips a generation.

Follow it back far enough and every living human being on Earth arrives at the same woman. Scientists call her Mitochondrial Eve. She lived in Africa somewhere around 150,000 to 200,000 years ago. She was not the only woman alive in her time — but she is the one from whom every single person now breathing inherits their mitochondria, in a line that has not broken once in seven or eight thousand generations.

The engine humming in your cells tonight is, in the most literal biochemical sense, the same lineage of engine that hummed in a woman who watched the Ice Age from the inside. Nothing about you is as new as you feel.

The cells that never leave

You have probably heard that your body replaces every cell every seven years, so that you are constantly becoming a brand-new person. It is a lovely idea. It is also mostly false.

Some of your cells are never replaced. Not once. You will die with the exact same ones you were born with — or older.

The lens of your eye is one. The cells at its very center were made before you were born and are never renewed, never swapped out. You are reading these words through tissue as old as you are — older, at the core.

Most of the neurons in your cerebral cortex are another. The thinking part of your brain runs, for a lifetime, on cells you have had since the beginning. And your heart — the organ I have spent my life listening to — turns over so slowly that most of its muscle cells are as old as you are. You will very likely die with many of the ones you were born with still beating.

And the oldest cells of all, in a woman’s body, are the eggs. Formed before her birth. Frozen mid-division, holding their breath, for decades. The cell that became you may have waited, silent and paused, for thirty or forty years before its moment came. There is nothing else in human biology that waits that long to do its one job.

Your mother is still carrying you. So are you carrying your children.

Here is the fact that undoes people.

When a woman is pregnant, cells do not only flow from mother to child. They cross the placenta in both directions. Some of the baby’s cells migrate into the mother — and they do not leave when the pregnancy ends. They stay. For years. For decades. Possibly for the rest of her life.

They have been found woven into the mother’s blood, her skin, her thyroid, her liver. In a 2012 study, researchers examined the brains of women who had died and found male DNA lodged inside the brain tissue of the majority of them — cells that could only have come from the sons they once carried, still present in the mother’s brain many years later.

The word for this is microchimerism, and it means something plain and staggering: your mother has almost certainly been carrying living pieces of you inside her body, in her organs, in her brain, since the day you were born.

And as a cardiologist, this is the part that stops me. In animal studies, when a mother’s heart is injured, fetal cells from her pregnancy travel to the wound, settle into the damaged muscle, and begin to take on the identity of heart cells — as if the child were trying to help repair the mother from the inside. Fetal cells have been found nestled in human maternal hearts as well. Whether they truly heal us is still being worked out with the caution such a claim deserves. But the cells are there. The child, in some real cellular sense, moves toward the mother’s wound.

So if you have carried a child, you are not only yourself. You are a mosaic. You are wearing them.

You are carrying people you have never met

Now stack it, the way we stacked the eggs.

Because cells pass both directions, a mother holds cells from each of her pregnancies — and she can pass some of those cells along, through her own body, into the next baby she carries. Which means a younger child can end up carrying the cells of an older sibling. And cells from the grandmother, passed down through the mother, can reach the grandchild.

You may be carrying a fragment of your older brother. Of a sister who came before you. Of a grandmother who died before you could remember her face. Not as memory. As tissue. As living cells inside you right now, that were never yours, from people you were never in a room with.

The body, it turns out, keeps everyone.

And older still

Go all the way down, past the cells, past the DNA, to the atoms themselves — and the age becomes almost unbearable.

The calcium in your bones. The iron in your blood that carries the oxygen your heart just pushed. The carbon in every strand of you. None of it was made on Earth. It was forged in the cores of dying stars and flung across the galaxy in explosions that happened billions of years before the Sun existed. You are quite literally assembled from the ash of stars that died so completely that their atoms had nowhere to go but here.

And the hydrogen — the hydrogen in every drop of water in your body, in your blood, in your tears — is older than the stars. It has existed, almost unchanged, since the first minutes after the beginning of the universe itself.

You are the youngest thing you know, built entirely out of the oldest things there are.

What the Kabbalists said, long before the microscope

The Kabbalists arrived here first, and without a single lens.

They taught that every soul destined to live was already present at the very beginning — folded within Adam, the first human, and held afterward in a hidden treasury the Talmud calls the Guf: the reservoir of souls, waiting their turn to be born. The Messiah, the sages said, cannot come until the Guf is emptied, until every waiting soul has descended into a body. Nothing, they insisted, ever truly begins. It is only revealed. Generation nested inside generation, all the way back to the first light.

What the biology now whispers, they said plainly: you were always here. Waiting inside the ones who came before you. Carried by people who did not know they were carrying you.

And notice the road it travels down. The mitochondria pass mother to daughter to daughter, unbroken, never once through a man — the very path by which the tradition says a soul’s deepest belonging descends. The Kabbalists had a name for the light a mother hands her child without ever manufacturing it herself: the Shechinah, the Divine presence that is not created new in each generation, only transmitted — from one vessel to the next, hand to hand, since the beginning.

A flame lit from a flame. Never a new fire. Always the same fire, passed on.

So here is where all of it lands.

A woman pregnant with a girl is, in the most literal sense the language allows, carrying her grandchildren too. Every woman alive began inside a woman she may never have met, in a body that had not yet been born. You are running on engines that were switched on before your mother could walk. You are carrying cells of the dead and the not-yet-arrived. You are built from starlight and from the first breath of the universe.

You did not begin at your birth.

You are the current, living end of a line of light that has never once — not for a single generation, not for a single instant — gone out.

And now it is burning in you.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

Doctors are editing the human manuscript to erase diseases at their source, growing replacement organs from a patient’s own cells, and building a living digital twin of you so a treatment can be tested before it ever touches your body.

The sentence every doctor dreads — “there’s nothing more we can do” — is quietly dying, and inside this piece are the twenty reasons why, most of them already here and coming for a hospital, a wrist, or a loved one near you.

I want to be careful here, because medicine has been oversold before. But something real is happening, and I don’t think most people have felt the size of it yet. The future of medicine is not a prophecy anymore. It is a shipment already in transit — and some of it has already been signed for.

Let me show you what I mean. Twenty technologies. Not twenty daydreams. Twenty forces that are going to touch you, or someone you love, sooner than you think.

Movement One: The doctor in your pocket, the doctor in your skin

For all of human history, health care happened when you finally went in. You waited until something hurt, made an appointment, and hoped it wasn’t too late. That entire model is being turned inside out.

1 · AI Medical Assistants. Imagine a tireless clinical mind that has read every study, forgotten nothing, and is available at 3 a.m. when your fear is loudest. Not to replace your doctor — to make your doctor superhuman, catching the drug interaction, the subtle pattern, the question you were too embarrassed to ask.

2 · Advanced Wearable Health Monitors. The watch on your wrist already reads your heart rhythm and can flag atrial fibrillation before you feel a single flutter. As a cardiologist, let me tell you plainly: that stroke it quietly prevents is a stroke you will never know you avoided. The next generation will track blood pressure, oxygen, glucose, and sleep as a continuous story instead of a once-a-year snapshot.

13 · Smart Biosensors. Sensors thin as a tattoo, worn on the skin or dissolving inside the body, whispering a live feed of your chemistry. The body has always been talking. We are finally learning to listen in real time.

15 · Remote Patient Monitoring. The hospital is leaving the building. Heart-failure patients monitored from their own kitchens. Rural grandmothers seen by specialists a thousand miles away. Care that follows the patient home instead of trapping the patient in a waiting room.

17 · Smart & Rapid Diagnostics. The days of “we’ll call you with the results next week” are ending. Answers in minutes, at the bedside, in the pharmacy, eventually on your bathroom counter. In medicine, time is tissue. Time is brain. Time is life.

8 · AI-Powered Medical Imaging. Algorithms now spot tumors, bleeds, and fractures that a tired human eye can miss at the end of a long shift — and they never have a long shift. This is not the machine replacing the radiologist. It is the machine handing the radiologist a second, sleepless set of eyes.

Movement Two: Rewriting the code of life

Here is where prophecy becomes documented fact. Sit with these.

3 · Personalized Genetic Medicine. For a century we practiced medicine for the average patient — a person who does not exist. Now we can read your individual code and choose the drug, and the dose, meant for you. The same pill that heals one person harms another. Finally, we can tell the difference before we prescribe.

7 · CRISPR Gene Editing. In December 2023, the FDA approved the world’s first CRISPR therapy for sickle cell disease and beta thalassemia — a genetic disease, corrected at its source. In the pivotal trial, nearly every patient walked away free of the crushing pain crises that had defined their entire lives.

Then it got holy. In 2025, an infant known only as KJ was born at Children’s Hospital of Philadelphia with a rare metabolic disorder his body could not survive. Instead of spending a decade developing a treatment, a team designed a gene therapy for his single, specific mutation — a medicine that had never existed and will never be needed by anyone else on earth. A cure built for one child. As of 2026, more than 250 gene-editing trials are underway. We have learned to edit the manuscript of a human being.

We used to inherit our fate in our DNA. For the first time in the history of our species, we can respectfully argue with it.

18 · Multi-Omics Medicine. Your genes are only the first page. Now we can read the whole library at once — genome, proteins, metabolites, the microbes in your gut — and see you as the vast, interconnected system you actually are, instead of a single lab value on a single afternoon.

12 · mRNA-Based Therapies. The technology the world met during the pandemic was only the opening act. In August 2026, a personalized mRNA cancer vaccine — a shot custom-printed against the unique fingerprint of a patient’s own tumor — succeeded in a large Phase 3 melanoma trial. Earlier data had shown it cut the risk of the cancer returning or killing by nearly half when added to immunotherapy. Lung, kidney, bladder, pancreatic trials are following. We are teaching the immune system to hunt cancer by name.

11 · AI-Designed Medicines. Discovering a drug once took a decade, a billion dollars, and a great deal of luck. Artificial intelligence now designs candidate molecules in a fraction of that time, imagining compounds no chemist would have thought to draw. Diseases we have called “undruggable” for generations are getting a second look.

20 · Nanomedicine & Targeted Drug Delivery. Picture microscopic couriers that carry a toxic dose of chemotherapy only to the tumor and nowhere else — sparing the hair, the appetite, the strength, the dignity. Medicine’s oldest problem has been hitting the disease without wounding the patient. We are finally learning to aim.

Movement Three: Rebuilding the body

4 · 3D-Printed Organs and Tissues. Right now, someone dies waiting for a transplant that never comes. Now imagine printing the tissue — and eventually the organ — from the patient’s own cells. No waiting list. No rejection. No stranger’s tragedy required for your survival.

9 · Lab-Grown Replacement Tissues. Skin for the burned. Cartilage for the worn. Beating heart tissue, grown in a dish, being trained to repair a heart that has already broken. The body has always known how to heal. We are learning to give it more raw material to work with.

6 · Robotic Surgery. Surgeons already operate through incisions the width of a pencil, with instruments steadier than any human hand, translating a master’s decades of skill into movements finer than a heartbeat’s tremor. Less pain, less scarring, faster mornings-after. And a surgeon’s gift, no longer limited by the shake of an aging wrist.

16 · Advanced Prosthetic Limbs. Limbs wired into the nervous system that move by thought and send sensation back — the return of touch, of grip, of a hand a person can actually feel. I have learned that we do not only lose function when we lose a limb. We lose a piece of how we meet the world. This gives it back.

Movement Four: The mind, reconnected

5 · Brain–Computer Interfaces. In January 2024, a young man named Noland Arbaugh, paralyzed from the shoulders down, received a brain implant — and within weeks was moving a cursor, playing chess, and navigating his computer using nothing but his thoughts. By early 2026, more than twenty people were living with these devices, and researchers had begun work on an implant to restore sight to the blind. Let that land. A thought, lost to a broken spinal cord, finding its way back out into the world.

19 · Neurostimulation Therapies. Gentle, precise electrical signals are quieting the tremor of Parkinson’s, lifting depression that no medication could touch, and calming seizures before they start. We are learning the electrical language of the brain and beginning, carefully, to speak back.

14 · Augmented & Virtual Reality Medicine. Surgeons rehearsing an operation before making a single cut. Chronic pain eased without a single pill. Burn victims escaping their agony inside a snowscape while their dressings are changed. Stroke patients relearning to walk inside a game their damaged brain is willing to play. The mind is medicine — and we are finally prescribing it.

Movement Five: Medicine that finally knows you

10 · Digital Twins of Patients. This is the one that quiets me. Imagine a living virtual copy of you — your heart, your chemistry, your genes — where a doctor can test a drug, a stent, a surgery on the digital you before ever touching the real one. Medicine practiced on your twin, so that nothing has to be practiced on you. Trial and error, without the error.

What the machines cannot do

Let me step out of my white coat for a moment.

Every technology on this list is astonishing, and I believe most of them are good. But I have stood at enough bedsides to know a quiet truth: none of them, not one, is the actual miracle.

The gene edit buys a childhood. The wearable buys a grandmother her grandson’s wedding. The implant buys back a stolen thought. The nanoparticle buys another autumn, another argument, another ordinary Tuesday that a family will one day remember as sacred.

The machine restores the function. But it is the morning, the conversation, the reconciliation, the “I love you” said one more time, that restores the person. Technology can extend the vessel. It cannot fill it. That part has always been, and will always be, our work — and God’s.

So yes, be excited. Be genuinely, unapologetically excited. We are living through the most hopeful chapter in the history of healing. The sentence I dreaded for twenty-five years — there’s nothing more we can do — is finally, mercifully, starting to lose its grip.

But do not fall in love with the tools. Fall in love with the days they were built to give you.

Then go, today, and use one of yours well.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

So look at the outcomes with me. And look, clear-eyed, at the alternative — because the alternative is no longer the Democratic Party of my parents’ generation. It is a movement, loudest in its Democratic Socialist wing, that has told us plainly what it intends. I take people at their word. Here is why I’m voting Red.

1. Because I refuse to normalize the celebration of murder. An American was shot dead in front of a crowd for the crime of debating in public. That should have produced one universal reaction: horror. Instead, some public voices cheered, excused it, or reached for “well, hurt people hurt people.” There is a line in a civilization, and it is this: you do not celebrate the killing of the people you disagree with. A movement that blurs that line has lost the moral authority to govern anyone.

2. Because a nation without a border is not a nation. Compassion and chaos are not the same thing. A country is allowed to know who is entering it, on what terms, and in what numbers. Erasing the border doesn’t make us kinder — it makes us ungovernable, and it punishes first the legal immigrant who did it the honest way, and the working family whose wages and safety absorb the shock.

3. Because you cannot run a superpower on wishful thinking about energy. We are the greatest producer of oil and gas in human history, and that abundance is not a sin to be flagellated — it is leverage, prosperity, and national security. Declaring war on the very thing that heats homes and moves the economy, before any real replacement exists, isn’t idealism. It’s malpractice.

4. Because safety is the first civil right. Prosecuting crime, funding police, and keeping violent offenders off the street is not cruelty. It is the baseline promise a government makes to its citizens. A city that will not protect the weak from the predatory has failed at the one job that matters most.

5. Because antisemitism is now worn openly, and I will not pretend otherwise. I have watched hatred of Jews and hatred of the only democracy in the Middle East move from the fringe to the microphone — dressed up as politics, excused as protest. When a movement’s fluency in “anti-Zionism” always seems to land on Jewish students, Jewish businesses, and Jewish safety, I trust my eyes. A party that cannot name this evil plainly cannot be trusted to fight it.

6. Because I believe in biological reality and in parents. Girls deserve fair competition and safe locker rooms. Parents deserve to know what is happening to their children in the institutions they’re forced to trust. This isn’t hatred of anyone — it’s a refusal to sacrifice the safety and dignity of young women to a slogan.

7. Because “burn it down and rebuild it” is a threat, not a platform. The most honest thing the radical left has said is that if you elect them, you will not recognize this country afterward. I believe them. And I don’t want a country remade by people who are ashamed of it. You do not hand the keys to someone who tells you they intend to demolish the house.

8. Because free speech is the immune system of a free country. When government leans on platforms to bury inconvenient stories, when disagreement gets relabeled as “harm,” the disease isn’t the speech — it’s the silencing. A republic that can’t tolerate argument is already sick.

I love this country the way you love something you know isn’t flawless — fully, and without apology. America is not the villain of history. She is, still, the greatest engine of freedom and opportunity the world has ever built, and her strength lies in her traditions, her Constitution, and her stubborn faith in the individual.

That’s the real choice in November. Not between a perfect man and a perfect party — that ballot has never existed. It’s between imperfect stewardship of something worth preserving, and a movement that has told you, out loud, that it wants to tear it down.

I’m voting to preserve it. I’m voting Red.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

The internet has discovered this too, all at once. Your feed is now full of APOE4 threads, red-light helmets, peptides, and confident men promising that “almost half of dementia is preventable.” Some of it is the best public-health message of the decade. Some of it will separate you from your money and your judgment.

Let me give you both: the system that actually works, and the filter to tell the signal from the noise.

First, the one reframe that changes everything

If you carry APOE4 — the gene everyone is suddenly talking about — you did not receive a sentence. You received a change in the odds. Roughly one in five people carries at least one copy. One copy raises late-onset Alzheimer’s risk meaningfully; two copies raise it a lot more. And yet enormous numbers of ε4 carriers live long lives with intact minds. The gene loads the dice. It does not throw them.

Here is the fact that should reorganize how you think about this disease: the Alzheimer’s that appears at 70 often began its work at 40. The cascade runs slow and quiet — midlife vascular and metabolic injury, then inflammation, then amyloid, then the spread of tau, then, decades later, the failure of the synapses you were using to read this sentence.

That timeline is not depressing. It’s the whole opportunity. You may not be able to knock over the first domino. You have twenty or thirty years to slow every one that follows.

How to read the discourse without getting played

Before the protocol, the filter. Because you’re going to be sold a lot of things.

What the loud accounts get right — and they really are right:

• Prevention is midlife work. Not something you start at your first missed name.

• APOE4 is common and almost nobody tests for it. You have to ask.

• Lifestyle is not “cope.” The Lancet Commission, the U.S. POINTER trial, and the walking-and-tau data are real, peer-reviewed, and large. Dismissing them as soft is the actual anti-science position.

• Heart health and brain health share the plumbing. This is the truest sentence in the entire conversation, and I say it as the guy who works on the pipes.

What the same accounts oversell:

• “Almost half of dementia is preventable” as a personal promise. The real figure — about 45% of cases worldwide, across 14 risk factors — is a population estimate, what might happen if every one of those factors were erased from every life on earth. It is the best prevention map we have. It is not a coupon for 45% off your personal risk.

• One diet as destiny. Meat versus plants is not the ballgame.

• Peptides, gadgets, and psychedelics before blood pressure. If your biohacking budget has a red-light panel in it but your systolic is 145, you have been played.

• “Amyloid is dead.” The 2022 research-fraud scandal wounded a lot of trust, and it should have. But amyloid didn’t stop being part of the pathology because one paper was faked. It’s part of the story. It was never the whole story.

Keep that filter in your pocket. Now here’s what to actually do.

The system: boring, vascular, and overwhelmingly effective

1. Measure the board

You cannot manage what you refuse to look at. Do this once, then repeat the bloodwork yearly.

Genetics and family: APOE status (ε2/ε3/ε4), and a first-degree family history of dementia, heart disease, and diabetes.

The vascular-metabolic dashboard — the one that actually matters:

• Home blood pressure, measured over several mornings. In midlife, aim closer to a systolic of 120 than to “normal for your age.”

• ApoB (a better number than LDL-C alone), plus LDL-C, triglycerides, HDL.

• Fasting glucose, HbA1c, and fasting insulin or HOMA-IR.

• Waist circumference and body composition — not just BMI.

• hs-CRP if you want an inflammation snapshot.

Brain-adjacent: a hearing test, an eye exam, a dental and gum check, and a sleep-apnea screen if you snore or wake tired. Optionally, with your physician, the newer p-tau217 blood test.

Nobody screens APOE by default. Nobody. You have to be the one who asks.

2. Movement is the highest-ROI drug I know

In November 2025, Nature Medicine published one of the cleanest human studies on this we have — the Harvard Aging Brain Study followed nearly 300 cognitively healthy older adults for up to 14 years, with pedometers and repeated brain scans. The results are worth memorizing:

Daily stepsEffect in people with elevated amyloid3,000–5,000~3-year delay in cognitive decline5,000–7,500~7-year delayAbove ~7,500Benefit plateaus

Read those numbers again. Walking bought people years. And here’s the mechanistic beauty of it: exercise didn’t lower amyloid at all. It was linked to slower accumulation of tau — the protein that actually seems to drive the damage. You may not be able to clear the kindling. You can slow the fire.

The 10,000-steps number was always a marketing figure from a Japanese pedometer company. You don’t need it. You need to not be sedentary.

The prescription: floor of 5,000 steps most days, target 7,000–8,000. Add 150+ minutes a week of zone-2 cardio (the pace where you can talk but not sing), and 2–3 days of strength training. Muscle is metabolic insurance.

3. Sleep is the brain’s dishwasher

Deep sleep is when the glymphatic system — the brain’s overnight cleaning crew — flushes soluble amyloid out. The evidence for protecting sleep is far stronger than the evidence for any sleep supplement you’ll be sold.

Seven to nine hours, on a consistent schedule. Treat sleep apnea aggressively; it’s a double hit, both vascular and cognitive. And if you fix only one nighttime thing tonight: cut the evening alcohol. It fragments exactly the deep-sleep stage you’re trying to protect.

4. Metabolic and vascular health — the main event

Type 2 diabetes travels with substantially higher Alzheimer’s risk. Some researchers call the disease “type 3 diabetes” for a reason: same arteries, same insulin-signaling failure, same inflammation. The brain is the end organ.

So argue with your doctor, if you have to, for these: no diabetes (and if you’re prediabetic, reverse it); ApoB and LDL treated like cardiac prevention now, not waited on until you’re 70; blood pressure controlled in midlife, not after a stroke; visceral fat down.

Lipids used to be a heart target. They are now a brain target too.

5. Food: get the pattern right, then worry about your genotype

The best-supported eating pattern remains Mediterranean / MIND — vegetables, berries, extra-virgin olive oil, fish, legumes, nuts, and as little ultra-processed food as you can manage. Start there. That’s 90% of the win.

Now, two APOE4-specific wrinkles — and I want you to hold these as hypotheses, not commandments:

• Meat may not be the enemy it’s made out to be for ε4 carriers. A March 2026 study in JAMA Network Open, following a Swedish cohort of more than 2,100 adults for 15 years, found that higher meat intake was associated with slower cognitive decline and lower dementia risk — but only in people with the ε3/ε4 and ε4/ε4 genotypes. Processed meat looked worse for everyone. This is one observational study. It does not overturn Mediterranean eating. The reasonable synthesis: unprocessed meat, fish, and eggs can live comfortably in an ε4 diet; processed meat should not.

• Alcohol is not neutral for you if you carry ε4. The gene is tied to earlier weakening of the blood-brain barrier, which means alcohol lands harder on your brain than on your neighbor’s. The honest default is little to none.

6. The “soft” stuff that isn’t soft at all

Sensory and social inputs sound like wellness fluff. They are among the most cost-effective interventions in the entire Lancet list.

• Hearing aids if you have loss. Hearing loss is one of the single largest modifiable factors, and it doubles as a shield against isolation.

• Correct your vision. Cataracts and bad glasses are a fixable dementia risk.

• Stay socially obligated. Not “have friends” — obligated. A standing appointment, a club, a family role, a volunteer shift you’d feel bad missing.

• Do genuinely hard cognitive work. Language, music, a complex job, deliberate learning. Not crossword apps. Real difficulty.

The U.S. POINTER trial — 2,111 at-risk older adults, published in JAMA in 2025 — showed that a structured multidomain program (exercise, diet, cognitive and social challenge, health monitoring) beat a self-guided version on global cognition. Crucially, the benefit held across APOE4 carriers. Structure beats vibes. A plan you follow beats a better plan you don’t.

7. Cheap extras with a real signal

Floss and treat your gums — chronic periodontal inflammation for thirty years is a genuinely dumb risk to carry. Run a HEPA filter and stay indoors on high-AQI days. Wear the helmet; protect your head. And eat fatty fish, because ε4 carriers transport DHA into the brain less efficiently — test an Omega-3 Index if you want to be precise about it.

The frontier stack: interesting, weaker, easy to overrate

Here is where the internet loses its mind and its money. I’ll rank these the honest way — by evidence, not by how futuristic they sound.

• Near-infrared / photobiomodulation (”red light for the brain”). Early small trials in people who already have mild cognitive impairment are intriguing. There is essentially no evidence it prevents anything in healthy carriers. Reasonable to watch. Not first-line. Not before your blood pressure.

• GLP-1 drugs. Observational data hint at lower dementia risk, but a major oral-semaglutide trial failed to slow decline in early Alzheimer’s. Prevention is not the same as treatment. If you already qualify metabolically, consider it a possible bonus — not a reason to start.

• Cerebrolysin, peptides like Semax, rapamycin. Research territory or non-U.S. clinical traditions. Not DIY protocols.

If a number on your dashboard is off — blood pressure, ApoB, A1c, apnea, hearing — fixing that with your physician is worth more than every device in this section combined.

The 12-week plan, if you carry ε4 (or just want to be serious)

Weeks 1–2 — instrument the board. Get your APOE status if you don’t know it. Pull labs: ApoB, A1c, insulin, a full lipid panel, and a blood-pressure series. Book the hearing, vision, and dental checks. Screen for sleep apnea if there’s any hint. Wear a step tracker and learn your real baseline.

Weeks 3–12 — lock the four floors:

1. Steps at 7,000+ most days.

2. Three strength sessions, two cardio, weekly.

3. Sleep 7–9 hours, no late alcohol.

4. A Mediterranean-style plate, unprocessed protein you tolerate, ultra-processed food and cigarettes gone.

Also schedule: one recurring, non-optional social commitment; one cognitively hard hobby; and a blood-pressure and waist recheck at week 12. If a number is off, that’s your first appointment.

The bottom line

The most powerful things you can do for your brain are the least glamorous things I do for your heart. Move a lot. Sleep deeply. Keep your metabolism honest. Control your blood pressure. Use your mind hard. Take care of your teeth. Watch the frontier with interest and your wallet closed.

APOE4 changes the odds. It does not write the ending. And the pen, for once, is largely in your hand — starting a couple of decades before you think you need it.

Go get your blood pressure checked. Today. That’s not a metaphor.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

I have said it more times than I can count. As a cardiologist, I have spent my life at the border between what medicine can reach and what it cannot, and for most of my career that border has felt fixed — a coastline, not a frontier. We managed. We slowed things down. We bought time and called it victory, because often time was the only currency we had.

I am writing to you today because that border has begun to move. Not in a press release. Not in a promise. In three human beings whose stories broke in the last twelve months, and whom I cannot stop thinking about.

The first is a baby.

He was born with a mutation so rare it appears in roughly one child in 1.3 million. His body could not clear ammonia, so it built up in his blood like a slow tide, the kind that damages the brain and, in about half of these infants, ends their lives in the first week. He was too small for the transplant that might have saved him. No drug existed for what he had. In the old grammar of medicine, he was the sentence itself: nothing more we can do.

So a team refused the sentence and wrote him a new one. They read his exact mutation — his, no one else’s — and designed a CRISPR editor built for him alone, wrapped it in a lipid particle, and delivered it into his liver cells to correct the error at its source. From diagnosis to a custom-made, one-of-one therapy took about six months. He went home. His lethal disease is now a survivable one.

I want you to sit with the strangeness of that. Not a drug for a million people. A drug for one. His genome, his specific fracture, his specific repair — designed and delivered before his first birthday. The trial that grew out of his case is now opening to other children with other fatal metabolic mutations. Medicine has always been mass-produced. This was tailored.

The second is a number that just became a milestone.

Last week, for the first time, a personalized mRNA cancer vaccine succeeded in a Phase 3 trial — the large, randomized, gold-standard kind that separates hope from hype. Eleven hundred and thirty-seven melanoma patients, their cancers surgically removed, at high risk of return. The vaccine is not one shot for everyone; it is printed from each patient’s own tumor, a wanted poster handed to their immune system describing the specific enemy it must hunt.

Added to standard immunotherapy, it meaningfully cut the risk of the cancer coming back or spreading, compared to immunotherapy alone. It is not yet approved; the companies are now taking it to regulators. But understand what happened: the idea that we could teach a person’s own immune system to recognize their own cancer — an idea that has been almost working for a decade — finally cleared the bar that matters.

The third is a word we almost never get to use.

In pancreatic cancer, one of the cruelest diagnoses I know, an earlier personalized vaccine has produced immune responses still standing nearly four years after treatment in some patients. Early. Small. Not a cure. But in that disease, years is a word we rarely say out loud, and here it was, said plainly.

Notice what these three have in common. Each one is personalized — built from the patient’s own body rather than pulled from a shelf. And the step that used to make personalization impossible, the years of design, is collapsing toward months as our tools learn to read the language of biology and write back to it. That is the real revolution. Not a single miracle drug, but a shift in what kind of thing a treatment is.

Now let me be a physician with you, and not a hype man — because the internet is full of the latter this month, and you deserve better.

This is the beginning. It is not the finish line. One baby. One trial. A handful of patients in pancreatic cancer. The timelines are years, not months. Cancer is not “solved,” and anyone who tells you it will be by some specific date on the calendar is selling you something — a subscription, a stock, a fantasy. I have held too many hands to traffic in false springtime. The honest word is not cured. The honest word is possible — and possible was not on the table a decade ago.

But the direction is unmistakable. The tools to read a mutation and write a correction are no longer theoretical. They are in the laboratories, and now, for the first time, in living bodies. The question has quietly changed from can we? to how fast, how safely, and for whom? — which is a moral question, not a scientific one, and those are the ones worth staying awake for.

I keep returning to an old idea from the tradition I was raised in. The Kabbalists taught that at the beginning, the vessels meant to hold the Divine light shattered, and the sparks scattered into everything, and the work of a human life — tikkun — is to gather them, to mend what is broken, one fragment at a time. I used to read that as metaphor. Lately I read it as a job description. A single child, a single mutation, a single vessel repaired at its exact point of fracture. Rumi said the wound is the place where the light enters. Perhaps it is also, now, the place where we finally learn to let it back in.

I have spent my life on the wrong side of there’s nothing more we can do. I do not know the day that sentence finally dies. But I have watched it begin to, and I do not think most people understand how enormous that is. The impossible is quietly becoming a scheduling problem.

That is not a small thing to witness. It may be the largest thing our generation gets to see.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

Both groups deserve a straight answer. So let me give you the one I wish every patient walked in already knowing — because the truth about POTS is genuinely two things at once, and you need both halves.

It is real, badly under-recognized, and physically debilitating for the people who have it. And it is also over-attributed — a label increasingly stretched over symptoms that sometimes have a different, and often more fixable, cause. Understanding the difference is how you get actual help instead of a wrong turn.

What POTS actually is

POTS stands for Postural Orthostatic Tachycardia Syndrome, and once you understand the physiology, the whole thing makes sense.

Every time you stand up, gravity pulls roughly a pint of your blood downward into your legs and belly. In a healthy body, the autonomic nervous system — the automatic controller of heart rate, blood pressure, and blood vessel tone — reacts in seconds: it tightens the blood vessels in your lower body to push blood back up, and nudges your heart rate up a little to keep your brain supplied.

In POTS, that first step fails. The blood vessels don’t clamp down the way they should, so blood keeps pooling below. To compensate and keep blood reaching your brain, your heart does the only thing left to it: it races. Not a little — a lot. And critically, your blood pressure usually does not crash. That combination — a heart pounding hard on standing, without a big blood-pressure drop — is the signature of POTS.

That’s why the symptoms are what they are: lightheadedness and near-fainting when upright, a racing or pounding heart, crushing fatigue, exercise intolerance, and the “brain fog” that makes it hard to think clearly. Many patients also have nausea, bloating, headaches, poor sleep, and trouble regulating temperature. It can touch nearly every system in the body — even though the heart, gut, and nerves usually look structurally normal on standard tests. That normalcy is exactly why so many patients get told nothing is wrong, when something very much is.

Why it exploded — and who it hits

POTS overwhelmingly affects women — about 90% of cases — with onset most often between ages 13 and 29. It’s estimated to affect somewhere between 1 in 1,000 and 1 in 100 Americans, and that number has almost certainly climbed.

The reason is infection. In a large share of cases, POTS begins within about three months of a viral illness — and COVID changed everything here. Long COVID drove a real, documented surge; by some estimates, nearly a third of people with severe long COVID meet the criteria for POTS. Epstein-Barr, influenza, and other infections can trigger it too, as can major physical stressors like surgery, trauma, or pregnancy. It also travels with certain other conditions — joint hypermobility (including Ehlers-Danlos syndrome), mast cell issues, and migraines.

I want to say one thing as plainly as I can, because too many women have been told the opposite: POTS is not anxiety, and it is not “all in your head.” It is a measurable malfunction of the autonomic nervous system. Living with an uncontrollable racing heart and bone-deep fatigue certainly causes stress — but that stress is the consequence, not the cause. The average patient waits around two years for a diagnosis, often after being brushed off repeatedly. That delay is a failure of medicine, not of the patient.

So how do you actually know if you have it?

Here is the part that answers the question I get most — and it’s more objective and more reassuring than most people expect. POTS is not a vague feeling. It has clear, measurable diagnostic criteria, and the core test is simple enough to start at home.

The four things that define it:

First, chronic symptoms of orthostatic intolerance — worse when upright, better when lying down — lasting at least three months. Second, a sustained heart-rate rise of at least 30 beats per minute within ten minutes of standing (or at least 40 bpm if you’re between 12 and 19). Third, no significant drop in blood pressure when you stand — if your pressure crashes, that’s a different condition. And fourth, no other cause that better explains it.

The practical version, the “stand test,” is something any clinic can do and you can even trial yourself: lie down quietly for at least five minutes and record your heart rate and blood pressure. Then stand, and record both again at intervals for up to ten minutes, noting how you feel. A reproducible jump of 30-plus beats per minute with real symptoms — and no big pressure drop — is the finding that matters.

When it deserves a workup — and when the answer is somewhere else

This is where honesty matters most, and where I try to help my patients rather than just label them.

A racing heart when you stand up is a real symptom. But it is not automatically POTS. Several common, often more treatable things produce the exact same feeling, and a good doctor rules them out before settling on POTS:

Simple deconditioning — a loss of cardiovascular fitness after illness or a long stretch of inactivity — can cause a big heart-rate jump on standing that mimics POTS closely. Dehydration and low blood volume do it too. So do thyroid disease, anemia, adrenal problems, and certain medications — stimulants, some antidepressants, diuretics. Occasionally a genuine heart, lung, or rare hormonal condition is hiding underneath.

So the honest answer to “does this deserve a workup” is: if you have three-plus months of orthostatic symptoms and a real heart-rate rise on standing, yes — get the simple stand test, an ECG, and basic blood work (blood count, electrolytes, thyroid). That’s low-cost, low-risk, and it either confirms POTS or, just as valuably, points you toward the thing that’s actually causing your symptoms. What you don’t need, in most cases, is an immediate cascade of expensive specialist testing — tilt-table studies, Holter monitors, echocardiograms are for atypical or complex cases, not the starting point.

The goal isn’t to collect a fashionable diagnosis. It’s to find the true reason your body feels the way it does. Sometimes that’s POTS. Sometimes it’s something else entirely — and finding that is the win, because it may be more fixable than POTS is.

When — and how — it’s treated

Here’s the encouraging part: for most people who truly have POTS, the first and most effective treatments aren’t drugs at all. They deserve to be tried first, and many patients improve substantially on them alone.

The foundation is expanding your blood volume: more fluids across the day, and — this surprises people — significantly more salt, because salt helps your body hold onto that fluid and fill the tank the pooling keeps draining. This is done with a doctor’s guidance and individualized, since it’s not right for everyone (especially with high blood pressure or kidney issues). Next, lower-body compression garments — ideally waist-high — physically stop the blood from pooling. Avoiding triggers helps: heat, prolonged standing, big heavy meals, alcohol, dehydration.

And then the one that’s hardest but matters most: structured, gradual exercise — started lying down or seated (a recumbent bike, rowing, swimming) to take gravity out of the equation, then slowly progressed over weeks. Formal programs exist for exactly this. The catch, and it’s important: pacing is everything. Pushing too hard, especially if you have overlapping post-viral fatigue, can trigger a crash that sets you back. Slow and consistent beats aggressive and inconsistent, every time.

Medications come in only when these measures aren’t enough to let you function — and they’re aimed at symptoms, not a cure. Options a specialist may use include drugs to slow the racing heart, drugs to tighten blood vessels, or drugs to help retain fluid. Started low, adjusted slowly. No pill cures POTS; the honest goal is to restore your life, measured by what you can do — not by chasing a perfect heart-rate number.

What I want you to take from this

If you’re one of the women wondering whether this is you: you are not imagining your symptoms, and you’re right to want answers. Do the simple stand test. Get the basic bloodwork. Start the fluids, salt, and compression now, while you seek care — they’re safe, and they help many people before any diagnosis is even confirmed. And find a clinician who takes you seriously enough to do the honest workup: to confirm POTS if it’s there, and to keep looking if it isn’t.

Because being taken seriously cuts both ways. It means never being dismissed with “it’s just anxiety.” And it also means not being handed a label that stops the search before the real cause is found. You deserve the truth about your own body — and for most people, with the right approach, real improvement is genuinely possible.

I write clear, honest explanations of the conditions my patients actually struggle with — the science, the nuance, and the practical steps, without hype or dismissal. If you want medicine explained straight, come join me.

Blessings,

Afshine “Ash” Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

🏅 Castle-Connolly Nationwide Top Doctor (Since 2008) 🌟 Los Angeles Magazine Super Doctor (Since 2010) 🇺🇸 LA Style Magazine Top 100 Doctors in America (2024)

📬 Subscribe: substack.com/@afshineemrani 📚 Books: Amazon Author Profil

For all of history, medicine has been built around the average patient: the average dose printed on a label, the average risk calculated from a population study, the standard treatment that works for most people in the middle of the curve. This was never a philosophical choice. It was a limitation. We simply did not have the tools to read and rewrite biology at the level of a single individual, so we treated everyone according to the average and adjusted by trial and error.

That limitation is now falling away. The common thread running through all four of this week’s announcements is that we are gaining the ability to build medicine for one specific person — to read an individual’s biology precisely, and increasingly to reprogram it. This article explains each breakthrough in plain terms, how each one actually works, and how they connect into a single trend. I’ll keep it accurate rather than dramatic, and I’ll be clear about what is proven and what is still early.

Let’s take them one at a time.

1. A personalized cancer vaccine passed a major clinical trial

What it is. A cancer “vaccine” that is custom-manufactured for one patient, based on the specific mutations in that patient’s own tumor. Note the word “vaccine” is somewhat misleading here: this does not prevent cancer the way a flu shot prevents flu. It is a treatment, given after surgery, to stop an existing cancer from coming back.

How it works, step by step. This is the part worth understanding, because it’s genuinely different from older cancer treatment.

First, surgeons remove the tumor. Scientists then sequence the tumor’s DNA and compare it, letter by letter, to the DNA of the patient’s healthy cells. Cancer arises from accumulated genetic mutations, and those mutations cause the cancer cells to produce abnormal proteins — called neoantigens — that appear on cancer cells and essentially nowhere else in the body. These are, in effect, molecular flags unique to that person’s cancer. No other patient’s tumor carries the same set.

Next, a computer algorithm analyzes those mutations and selects up to about 34 of them that the patient’s immune system is most likely to be able to recognize and attack. Those selected targets are encoded into a strand of messenger RNA (mRNA) — the same class of molecule used in the COVID vaccines — wrapped in a tiny fat particle called a lipid nanoparticle, and injected. The patient’s own cells read the mRNA and briefly display the cancer’s molecular flags, which trains the immune system’s T-cells to recognize and destroy any cell carrying them. The vaccine is given together with a second drug (Keytruda, a checkpoint inhibitor) that removes a molecular “brake” cancers use to hide from the immune system, so the newly trained T-cells can finish the job.

The result. In a Phase 3 trial of 1,137 patients with high-risk, surgically removed melanoma, the personalized vaccine plus Keytruda outperformed Keytruda alone: it reduced the rate of cancer recurrence and reduced the rate of spread to distant organs. This is the first time in medical history that an mRNA-based cancer therapy has succeeded in a Phase 3 trial. Earlier-stage data had shown roughly a 49% reduction in the risk of recurrence or death. Trials in lung, bladder, and kidney cancers are already underway.

The honest limits. The trial measured whether the cancer returned, not yet whether patients ultimately live longer overall — that longer-term survival data is still being collected. The full statistical details (exact hazard ratios and confidence intervals) have not yet been published. And the therapy is complex and expensive to manufacture individually. But the core proof-of-concept — that a made-to-order immune therapy can beat the standard of care in a large randomized trial — is now established.

2. A one-time treatment for high cholesterol that doesn’t permanently change your DNA

What it is. An experimental treatment (from a company called Scribe) intended to lower “bad” cholesterol (LDL) with a single dose that lasts for years, aimed at the world’s leading cause of death: cardiovascular disease.

The background you need. A gene called PCSK9 helps control how much LDL cholesterol stays in your blood. Turn that gene down, and LDL drops substantially. We already know this works — there are two approved drugs (Repatha and Leqvio) that block PCSK9. What’s new here is not the target. It’s the method and the durability.

How it works, and why it’s different from ordinary CRISPR. You may have heard of CRISPR as “gene editing” — molecular scissors that cut DNA to change it. Cutting DNA is powerful, but permanent and risky: mistakes can’t be undone. This treatment does not cut DNA. It uses a deactivated version of CRISPR — the targeting system without the scissors — to place a chemical “off switch” on the PCSK9 gene. This is called epigenetic silencing: the underlying DNA sequence is left completely intact, but a chemical tag tells the cell to stop reading that gene. Because the DNA itself isn’t altered, the effect is designed to be potentially reversible. The whole package — the instructions for the silencing machinery plus a guide that steers it to PCSK9 — is delivered to the liver using the same lipid-nanoparticle technology used in mRNA vaccines.

The result. In non-human primates (monkeys), a single dose lowered LDL cholesterol by more than 50%, and the effect lasted nearly two years and was still ongoing. Higher doses reduced LDL by as much as 67–68%. Liver function stayed normal.

Why this matters. Today, preventing heart disease means taking pills every day, often for decades. But roughly half of patients stop taking their cholesterol medication within a year — and every gap allows more plaque to build in the arteries. This “adherence gap” is a major, well-documented cause of preventable heart attacks. A single treatment that holds cholesterol down for years would bypass that problem entirely.

The honest limits — and these are big. This is still animal data. The therapy is only now entering its first human trial, which is designed primarily to test safety, not to prove it works in people. Many treatments that look excellent in monkeys disappoint in humans. So this is a promising direction, not a proven therapy. It is the least clinically advanced of the four breakthroughs here — but potentially one of the most consequential if it holds up.

3. Artificial intelligence designed working proteins — confirmed in a real laboratory

What it is. AI models (from Anthropic — the company that also makes the assistant this article was drafted with; the results were independently verified by outside labs) were used to design brand-new proteins from scratch, and those designs were then physically built and tested.

What a “protein binder” is, and why it’s important. Many modern drugs work by binding — latching tightly onto a specific target molecule in the body to block it, activate it, or change what it does. A “binder” is a small protein engineered to grip a chosen target. Designing a good one from scratch (called de novo design) has traditionally required a trained protein engineer months of painstaking work per target. It is one of the foundational, rate-limiting steps in developing new medicines.

What actually happened. The AI was given a set of 15 biological targets and tasked with designing binders for all of them, working largely on its own — researching each target, choosing where to bind, running specialized design tools, and ranking its best candidates. Then two independent contract laboratories, Adaptyv Bio and Twist Bioscience, physically synthesized the AI’s designs and tested them in the lab, without modification.

The result. The designs successfully bound their targets in 14 of the 15 cases, with an overall success rate around 27% — more than double the 10–15% typical of standard industry campaigns. On one difficult target, the AI achieved a 40% success rate, compared with under 4% for human entrants in a prior competition on the same target.

Why it matters, and the honest limit. The significance is speed: a step that used to take months can now be compressed into an afternoon, and the results survived real-world laboratory testing rather than existing only on a screen. The important caveat is that a protein that binds its target is only the first step toward a drug. It still has to prove it is safe, stable, and effective inside a living body — the long and difficult part. But the design bottleneck that gated everything downstream is easing dramatically.

4. The monitoring layer: tracking microscopic disease in a tube of blood

What it is. A quieter set of advances — companies integrating genetic sequencing, artificial intelligence, and “liquid biopsy” into single platforms. This got less attention, but it is what makes the other three usable in practice.

The problem it solves. Suppose you can now build a personalized cancer vaccine or a one-time gene therapy. You still need a way to know, in real time, whether it’s actually working — ideally long before a tumor grows large enough to appear on a scan. You need a way to see inside the body between doctor visits.

How it works. A liquid biopsy is a blood test sensitive enough to detect the faint genetic traces that cancer cells shed into the bloodstream. By first building a genetic “fingerprint” of a patient’s specific tumor, doctors can then scan the blood at each follow-up for that exact signature — sometimes catching a recurrence months earlier than imaging could. If the signal reappears, treatment can begin while the disease is still microscopic and most treatable.

Why it matters. Precision therapy needs precision surveillance. A powerful personalized treatment is far more useful when paired with a sensitive way to measure whether it’s working and to catch any return early. This monitoring layer is what turns a one-time treatment from a gamble into a managed, trackable process.

How these four connect — the actual point

Individually, each of these is interesting. Together, they reveal a single trend, and it comes down to a shared toolkit.

Every one of these breakthroughs is built from the same handful of technologies that also made the rapid COVID vaccines possible: messenger RNA (programmable instructions for cells), lipid nanoparticles (a delivery system to get those instructions into the body), fast genetic sequencing (the ability to read biology cheaply and quickly), CRISPR (the ability to target and now rewrite or silence specific genes), and artificial intelligence (the ability to design biological molecules and interpret complex data). These five capabilities matured at roughly the same time, over the past decade, and this week we saw them applied — separately but simultaneously — to the two conditions that kill more people than anything else on Earth: cancer and cardiovascular disease.

The deeper shift is in the strategy of medicine itself:

• In cancer: moving from “remove the tumor, then apply broad treatments and hope” toward “read the tumor’s specific mutations, train the immune system against them, and monitor the blood for any return.”

• In cardiovascular disease: moving from “take pills every day for the rest of your life” toward the possibility of a single, durable treatment that addresses a root genetic driver.

• In drug development: moving from years of laboratory trial-and-error toward AI-assisted design that produces viable candidates faster, then synthesizing and testing them quickly.

In each case, the direction is the same: from reacting to disease after it appears, toward reading and reprogramming biology to prevent or intercept it — and from treatments designed for the population average toward treatments built for the individual. That is why four “stock stories” are really one story.

What to actually conclude — with appropriate caution

It would be a mistake to read this and conclude that cancer and heart disease are solved. They are not, and honest framing matters.

The personalized cancer vaccine is the most advanced of the four, with a genuine Phase 3 success — but it still owes us long-term survival data and full published statistics, and it is complex to manufacture. The one-time cholesterol therapy is striking but has been demonstrated only in animals so far, and is just now entering its first human safety trial; it could still fail in people, as many promising therapies do. The AI-designed proteins are an impressive and independently verified first step, but binding a target is a long way from an approved drug. And the monitoring tools, while real, are still being validated and integrated into routine care.

In this field, enthusiasm routinely runs ahead of proof, and some of these efforts will stumble. That is normal, and it is worth stating plainly.

But the underlying direction is no longer in question. The tools to read and rewrite biology at the level of the individual now exist and are working, and they are being pointed directly at the diseases that cause the most human death. The wall between “average medicine” and “medicine designed for a specific person” has been breached. What happened this week is not the finish line. It is credible, measurable evidence that the shift is real and already underway.

follow me on X to read more

I write plain-language explanations of what’s actually happening at the frontier of medicine — the science, the mechanisms, and an honest accounting of what’s proven versus what’s still early — without the hype and without the jargon. Subscribe for clear, accurate coverage of the changes that are going to shape how you and the people you love are treated.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

For the first time in history, doctors can take a biopsy of your specific tumor, read its unique DNA mutations — the exact fingerprint no other cancer on earth shares — and build a custom mRNA blueprint written for one human being. Yours. It doesn’t poison the cancer. It doesn’t burn it. It teaches your own immune system exactly what to hunt.

And this week, a Phase 3 trial confirmed it works.

I’ve spent my life as a physician, and I did not expect to see this so soon. Let me show you what actually happened, how the thing is built — because the how is the most astonishing part — and then, at the end, let me answer the hard and fair questions you have every right to ask about anything with “mRNA” in its name.

But first, the wonder. Because it is real, and it is enormous.

What just happened

Added to the best immunotherapy we already had, this individualized cancer vaccine has been dramatically cutting the odds that high-risk melanoma comes back. In the earlier trial, the combination reduced the risk of recurrence or death by 49%, and the risk of the cancer spreading to distant organs by 62%, compared to the standard treatment alone.

This week, the large Phase 3 trial — over a thousand patients — met its goal. It significantly delayed recurrence and slowed the spread of cancer to distant organs, once again beating the current gold standard. It is the first time in all of medical history that an mRNA-based cancer therapy has won a Phase 3 trial.

That is not a modest tweak. That is a different trajectory for a human life.

And melanoma is only the first door. The very same approach is now being tested across lung, bladder, and kidney cancers — a whole program of trials, racing forward at once. What you are watching is not a single drug. It’s a platform — a repeatable method that could, in principle, be pointed at one cancer after another.

How the magic is actually made

This is the part that gave me chills as a doctor, and I want you to feel it too, because it sounds like science fiction and it’s happening in real laboratories right now.

Step one: read the enemy. Surgeons remove the tumor. Scientists then sequence its DNA and compare it, letter by letter, to the DNA of your healthy cells. The differences — the mutations the cancer accumulated as it grew — are its signature. And here is the key: those mutations produce abnormal proteins, called neoantigens, that appear on cancer cells and essentially nowhere else in your body. They are the cancer’s fingerprints, and they are unique to you. No other person’s tumor has the same set.

Step two: choose the targets. An algorithm sifts through those mutations and predicts which of them your particular immune system is best equipped to recognize and attack. From potentially hundreds, it selects up to a few dozen of the most promising — a personalized most-wanted list.

Step three: write the instructions. Those chosen targets are encoded into a strand of messenger RNA — the same molecular language your cells use every second of every day to make proteins. The mRNA is wrapped in a microscopic bubble of fat, a lipid nanoparticle, that carries it safely into your cells. Start to finish, this bespoke medicine is designed and manufactured for one person in a matter of weeks.

Step four: train the hunter. Injected into your body, the mRNA instructs your own cells to briefly display the cancer’s fingerprints — like handing your immune system a photograph of the criminal. Your T cells learn the face. And then they patrol, for months, hunting down any cancer cell that wears it. The vaccine doesn’t fight the cancer itself. It turns you into the thing that fights it.

Pair that with an immunotherapy drug that takes the brakes off the immune system, and you get what the trials are showing: a body newly able to find and destroy the microscopic cancer cells that surgery inevitably leaves behind — the ones that, left alone, become the recurrence that kills.

Why this is bigger than one disease

Understand what this means, because it reaches far past melanoma.

For all of history, we fought cancer with blunt weapons. Cut it out. Burn it with radiation. Flood the entire body with chemotherapy and pray the cancer dies before the patient does. We were swinging a hammer in the dark, and the hammer hit everything — the tumor and the person holding it.

This is a blueprint instead of a hammer. A therapy designed, in effect, atom by atom for one individual’s disease, that recruits their own biology to do the hunting with a precision no drug flooding the whole bloodstream could ever match. We are watching medicine shift, in real time, from managing cancer to hunting it. From reacting to a disease after it declares itself to teaching the body to hold the line before it ever spreads.

We were told, for decades, that personalized cancer vaccines were a thirty-year dream — always just over the horizon, never quite here. They are here. In real patients. With real data. In our lifetime. I say this as a doctor who knows precisely how rare these moments are, and how many false dawns the history of oncology contains: this is one of the most genuinely hopeful things to happen in the entire history of the field.

To be alive at the hour when human beings learned to teach the body to cure itself is a gift I don’t take lightly.

The questions you’re right to ask

Now — because I promised you honesty alongside the wonder, and because hope without honesty is just marketing — let me answer the hard questions directly. Not to dampen any of the above, but because a breakthrough this real can withstand real scrutiny, and the people asking these questions are being rigorous, not difficult.

Who is behind it, and how large is the evidence? This therapy is jointly developed by two pharmaceutical companies, Merck and Moderna. Industry funds the trials — a fair thing to keep in mind, and a reason to insist on independent, peer-reviewed data rather than press releases before anything becomes routine. The evidence was built in stages, each larger than the last: a Phase 1 in roughly 140 patients established safety, a Phase 2b of 157 produced the striking recurrence numbers, and the new Phase 3 randomized 1,137 patients with high-risk melanoma — and met its endpoints at a prespecified interim analysis, with a safety profile consistent with the earlier studies and no new safety signals.

How solid are the numbers, honestly? In the smaller Phase 2b trial, the benefit was real but the confidence intervals were wide — because 157 people is a small group, and small trials speak with less certainty. That is exactly why the Phase 3 existed: to see whether a dazzling early signal held up in a far larger population. It did. But the full Phase 3 details — the exact hazard ratios and p-values — haven’t been published yet; they’re coming at a medical meeting and in peer review. And these trials measured whether cancer came back, not yet whether people ultimately live longer overall. Delaying recurrence is a strong, encouraging sign that usually points toward longer survival, but the overall-survival data are still maturing. I’d rather tell you that than let you believe more than the evidence yet supports.

What about safety — where does it go in the body, and what does it do? Honest pharmacology, in plain terms: the lipid nanoparticle concentrates first at the injection site, then drains to the nearby lymph nodes — which is exactly where you want it, because that’s where the immune system is trained. The particles that reach the bloodstream distribute mostly to the liver, and to a lesser extent the spleen — which is why those are the organs researchers monitor. The mRNA itself is transient: your cells read it, make the target proteins, and then break it down within days. It does not enter the nucleus and it does not integrate into your DNA — it cannot rewrite your genome; that isn’t how the biology works. What it is, by design, is pro-inflammatory — that’s how it wakes the immune system up — and that same quality is the source of the reactions people can feel, from fever and fatigue to, rarely, more significant responses. There is also a specific risk worth naming: because the therapy trains the immune system to attack mutated proteins, there’s a theoretical risk of off-target autoimmunity if a chosen target too closely resembles a normal one. It’s minimized by heavy computational screening — but minimized is not zero, and it’s a fair thing to ask any oncologist. And the honest overarching limit: this is a new modality, so its very-long-term safety data are, by definition, still being written.

And yes — after COVID

I won’t pretend the last five years didn’t happen, or that the word “mRNA” now lands on neutral ground. It doesn’t. Many thoughtful people came out of that era with real questions, and some with real injuries. Their caution deserves respect, not a lecture.

So here is what I most want to say. Trust is the wrong frame — and it always was. No one should hand their life to a technology as an act of faith: not mRNA, not chemotherapy, not surgery, not anything. What medicine actually asks for is not trust but informed, individual consent — you, your specific situation, your own history, the real data and the real risks, and a physician who tells you the truth, together deciding whether the benefit is worth the cost for you. Someone who has had a severe reaction to something before is not being irrational to weigh that heavily; that history belongs at the very center of the decision.

And the context genuinely matters. A vaccine given to a hundred million healthy people to prevent an infection, and a therapy given to a cancer patient whose disease is likely to return and kill them, are simply not the same decision — even when they share a delivery technology. The risk you’re willing to accept changes entirely with what sits on the other side of the scale. For a healthy person, the bar should be very high, and caution is appropriate. For someone facing a high-risk cancer that may come back and spread, a 49% reduction in recurrence is weighed against a mortal threat — and that person may reasonably say yes, with full information, in a monitored setting. Another person, with a different history, may just as reasonably say no. Both are good medicine, because both are individual.

That’s the whole point. The answer to “should people trust mRNA to fight cancer” isn’t yes and isn’t no. It’s: it depends entirely on who you are, what you’re facing, and what your own body has already shown you — and no honest doctor should try to make that decision for you from a headline.

So here is where I land, holding both truths at once and dropping neither: this is a genuine scientific miracle, one of the most hopeful advances I’ve witnessed in a lifetime of practice — and it is a new, powerful therapy that deserves every hard question you can bring to it. Those two things are not enemies. Held together, they are exactly how medicine is supposed to work.

Wonder, with your eyes open. That’s the only kind worth having.

I write the version your doctor would give you if he had the time and nothing to sell — the awe and the fine print in the same breath. The deeper work lives here: the heart, longevity, the frontiers of medicine, and how to think clearly about your own body in a noisy world. Subscribe for the honest conversation — the hope with the caveats left in.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

For women in midlife, it may be one of the highest-return things you can buy for pennies a day — and it works on your brain, not just your body.

Let me show you the evidence, because almost no one is telling women this.

Start with the part you might already know. In postmenopausal women, 5g of creatine monohydrate daily paired with resistance training produces small but real gains in lean mass and leg strength. The key word is paired. Without the lifting, you get almost nothing. Creatine doesn’t replace the work — it makes the work pay off more. That alone matters enormously in a decade when women are quietly losing the muscle that protects their metabolism, their bones, and their independence.

But here’s the part most women have never heard.

Your brain runs on ATP — cellular energy. And when estrogen drops in perimenopause, brain energy metabolism takes a hit. That’s a real, physical driver of the “brain fog,” the slower recall, the walking-into-a-room-and-forgetting. It was never just stress or “getting older.” Your brain’s power supply changed.

Creatine helps regenerate that energy fast. And it shines brightest exactly when the brain is under strain — poor sleep, mental fatigue, aging, hormonal transition. Which is a precise description of the midlife window.

The first dedicated menopause brain trial just landed — 36 peri- and menopausal women, 8 weeks. The creatine group improved reaction time by 6.6% (placebo: 1.2%), raised the creatine level in their frontal lobe by 16.4%, and trended toward fewer mood swings. First human imaging proof that creatine actually reaches and fuels the menopausal brain.

And here’s the part that caught my eye as a cardiologist: it also nudged their cholesterol profile in a favorable direction. A supplement being studied for brain fog quietly helped the heart too. That’s the kind of two-for-one I spend my career looking for.

Why women specifically? Two reasons. Women start with lower natural creatine stores than men. And the estrogen decline disrupts brain energy on top of that. So women may have the most to gain from the one cheap, safe tool that directly raises brain creatine and backs up ATP when the tank is running low.

Be clear-eyed: this won’t make you a genius overnight. The effects are modest, and they’re clearest when your brain is under load. Creatine builds up over weeks — the clarity isn’t a switch, it’s a slope. But stack the muscle, the strength, and the cognitive edge together, keep it consistent for months, and it’s one of the highest-ROI habits available to a woman in this chapter.

The protocol is almost insultingly simple:

5g of creatine monohydrate. Every day. No loading phase needed. Pair it with progressive lifting. Give it months, not days. Monohydrate is the most-studied, cheapest, most practical form — don’t overthink the fancy versions.

It’s safe for healthy women, with side effects no different from placebo. Check with your doctor first if you have kidney issues.

So stop letting the word “creatine” conjure a bro in a tank top.

It’s a midlife tool for the body and the brain. It helps you keep the muscle, keep the strength, and keep the sharpness that this decade tries to quietly take.

Take the 5 grams. Lift. Stay consistent.

Keep what’s yours.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

For as long as I’ve practiced — twenty-five years now — medicine has treated men’s sexual health as a problem to solve and women’s as a mystery to shrug at. Men got research, drugs, dignity, and a diagnosis. Women got a hand on the shoulder and some version of: it’s stress, it’s your hormones, it’s just your age, it’s probably in your head.

That was never good enough. And it was never true.

About 40% of women report a sexual concern. Roughly 12% live with one distressing enough to genuinely affect their lives. That’s not a rare malfunction in a few unlucky women. That’s an enormous number of people being quietly told to accept something that, in most cases, can be understood, supported, and changed.

So here is the guide I wish every woman had been handed decades ago. The science, the tools that actually have evidence, the medical options no one mentioned — and the honesty the rest of it has been missing. I’m going to be direct and clinical, because you deserve information, not euphemism.

Let’s begin where the truth begins.

Your body is a system, not a mystery

The first thing almost no one explains: female sexual response isn’t one thing. It’s four.

Desire — the wanting. Arousal — physical and mental readiness, including blood flow and lubrication. Orgasm. Satisfaction — the whole experience landing as genuinely good.

Each runs on its own machinery — hormones, blood flow, the pelvic floor, neurotransmitters, sleep, stress, the relationship, the medications you take. Break one link and the whole chain can feel broken, but each breaks for entirely different reasons. Treat the wrong one and you’ll do everything “right” and feel nothing change.

And unlike male sexuality, a woman’s response is far more context-dependent and multifactorial. That is not a flaw to be fixed. It’s the design. Which is exactly why the “just take a pill” model was never going to fit — and why its failure to fit got blamed on women instead of on the model.

The real approach was always going to be layered: build the foundations, then add targeted tools. Consistency beats any single hack. And before anything else, a good clinician rules out the physical causes that love to masquerade as low desire — thyroid problems, anemia, diabetes, depression, and the genital tissue changes of menopause. So much “I just don’t want it” is actually untreated pain, exhaustion, or a fixable medical issue wearing desire’s clothing.

Now the map.

Foundation one: sleep is a sex drug

The single most powerful thing you can do for your sex life costs nothing, needs no prescription, and almost no one connects to the bedroom.

Sleep.

Poor sleep — insomnia, short nights, untreated apnea — is strongly linked to lower desire, harder arousal, more difficulty reaching orgasm, and more sexual distress. It isn’t subtle, and it isn’t your imagination. The exhausted body deprioritizes sex, because from a pure survival standpoint, sleep is mandatory and sex is optional.

Here’s the number that stops people cold: one extra hour of sleep has been associated with roughly a 14% increase in the odds of being sexually active the next day. One hour. Not a supplement, not a device — just giving your body what it was already begging for.

So aim for seven to nine hours. Women often need slightly more than men, thanks to hormonal and recovery demands. Hold your bedtime and wake time steady, because your hormones run on that clock. Dim the lights an hour before bed, get the screens out of your face, and build a real wind-down — breathing, a little stretching. Magnesium glycinate or tart cherry help some women. And be honest about alcohol: it feels relaxing, but it fragments sleep and flattens arousal.

And if you snore, wake unrefreshed, or a partner has watched you stop breathing at night — get evaluated for sleep apnea. Treating it can directly improve sexual function, and it protects your heart at the same time. Women’s apnea is wildly underdiagnosed, because it rarely looks like the male stereotype.

Foundation two: the muscle no one told you to train

There is a muscle group that governs arousal, lubrication, orgasm intensity, and whether sex hurts or feels wonderful. Almost no one trains it on purpose. Most women were never even told it could be trained.

The pelvic floor.

A stronger, better-controlled pelvic floor improves arousal, lubrication, orgasm intensity and control, and satisfaction — while reducing the pain and incontinence that quietly sabotage sex. This is among the best-supported non-drug interventions in all of women’s health; the reviews and meta-analyses are clear.

To find the muscles, squeeze as if you’re holding back gas. That’s the pelvic floor. The most common mistake is tensing the abs, glutes, or thighs instead — if those are firing, you’re missing the real muscle. Contract for three to five seconds, then fully relax for three to five; the relaxation matters as much as the squeeze. Build toward ten-second holds, three sets of ten, two or three times a day, and add quick one-second flicks for the fast-twitch fibers. Progress from lying to sitting to standing, and exhale as you contract. Smart biofeedback trainers with apps genuinely help technique and consistency.

Give it eight to twelve weeks. That’s when the change shows up.

But here is the caveat a responsible physician always adds: if you have pelvic pain, or a floor that is already too tight, more squeezing is exactly the wrong medicine — Kegels can make it worse. If you have pain, or no improvement after twelve weeks, see a pelvic floor physical therapist. That specialty is one of the most underused resources in women’s health, and it changes lives. Strength is not the only goal. Control and release are too.

The cardiologist’s secret: arousal is a blood-flow event

Here’s why a heart doctor, of all people, belongs in this conversation.

Arousal is, in large part, a blood-flow event — engorgement, lubrication, sensitivity, all driven by blood rushing to the genital tissue. And blood flow is my entire field. The same vascular system I watch to predict heart attacks is the one that decides whether a woman’s body can respond. They run on the same endothelium — the delicate, one-cell-thick lining inside every vessel you own.

When that lining thrives, arousal comes more easily. When it struggles — from high blood pressure, high blood sugar, smoking, inactivity — arousal quietly gets harder. Same plumbing, same rules as the heart.

Which leads to a genuinely liberating truth: the “sexual” fixes and the “heart” fixes are the same fixes. Aerobic exercise — 150 minutes a week of brisk walking, cycling, or swimming — improves blood flow, hormones, mood, and body image, and the meta-analyses show it lifts female sexual function across every single domain. Even short fifteen-to-twenty-minute sessions show acute benefits for desire. You are not choosing between a healthy heart and a good sex life. They are the same project.

This is also why medicine is now testing blood-flow tools directly in women — topical sildenafil cream, the Viagra molecule applied locally, is showing promise in trials for arousal disorder, with fewer whole-body effects. The logic is identical to the one we’ve used in men for decades. We were simply slower to study it in women, as usual.

And one more thing you need to hear as a cardiologist’s patient, not just a reader: if your arousal has changed, that can be a vascular signal — an early readout of the same system that decides your cardiac future. Women’s heart disease is more underdiagnosed than men’s, not less. So take it seriously. Know your blood pressure and your blood sugar. Treat your circulation as though your sex life and your life both depend on it. Because they do.

The anatomy lesson most women never got

Most women were handed decades of shame and almost no accurate information about their own body. So let me give you the version that is simply true.

The clitoris has far more nerve endings than the vagina. For most women, it is the main event, not the warm-up. This single fact rewrites an enormous amount of unnecessary frustration: if penetration alone rarely gets you there, nothing is wrong with you — that is the statistical norm. Most women need direct clitoral stimulation to reach orgasm. The cultural script that said otherwise was written without the anatomy in front of it.

So the technique that actually works is unhurried: full-body arousal first, building sensation gradually, before narrowing to the genitals — because rushing to the finish fights your own biology. Then clitoral focus with light pressure and a consistent rhythm, responsive to feedback, with internal or G-spot stimulation added if you enjoy it. Some women love it, some don’t; both are entirely normal.

Devices belong here without a flicker of embarrassment. Vibrators — wand, bullet, air-pulse and suction styles — are linked in research to better arousal, orgasm, satisfaction, and lower distress. They are not a crutch; they reliably deliver the kind of stimulation the anatomy actually wants. Choose body-safe materials, clean them properly, and treat good lubricant as a pleasure upgrade rather than evidence that anything is wrong.

And the most important instruction, the one that quietly transforms relationships: explore solo first. You cannot guide someone to a place you have never mapped yourself. Learning your own responses is the fastest route to better partnered sex — and then communicating them, in real time, not as criticism but as a gift. “There, like that” is one of the most generous sentences you can say in a bed.

It’s not “all in your head” — but your head is a lever

For generations, “it’s all in your head” was used to dismiss women. Here is the honest version: your mind is a real, powerful, physiological part of your sexual response — not as an insult, but as a lever you can actually pull.

Stress, anxiety, body image, and relationship strain aren’t soft secondary factors. They are often the main ones. The nervous system that governs arousal cannot fully engage while it’s braced for threat — and modern life keeps it braced. You cannot relax into pleasure with your foot on the alarm. This is biology, not weakness.

And this is where the evidence gets genuinely strong. Mindfulness-based cognitive behavioral therapy and sex therapy have robust data for improving desire, arousal, and orgasm — not vague relaxation, but structured, studied methods for retraining how attention and pressure operate during intimacy. For many women this outperforms every supplement in existence. The core of it: lower the performance pressure, because the goal is presence, not a perfect response; use breath to shift out of alert mode; and place your attention on sensation instead of monitoring yourself from the outside. That self-watching — is this working, do I look okay, is it taking too long — is the single most common arousal-killer there is.

The relationship is part of the medicine too. Desire lives in safety, trust, and feeling wanted, not only in hormones. So if talking, mindfulness, or therapy is what you need, that is not the consolation prize after the “real” options. For a great many women, it is the real treatment. Seek it without a shred of shame.

The medical options no one told you existed

Most women with genuine, distressing low desire have never been told that real, studied medical treatments exist. They do — and you deserve to know the whole list.

There are options FDA-approved specifically for low desire. Flibanserin (Addyi) is a daily pill that adjusts the brain’s serotonin, dopamine, and norepinephrine, with a modest but real increase in satisfying encounters and desire and less distress; it’s now approved for pre- and postmenopausal women under 65, with cautions around drowsiness and alcohol. Bremelanotide (Vyleesi) is an on-demand option that works on the brain’s “wanting” circuitry rather than on blood flow; nausea is the common effect, and because it’s an injectable prescription with cardiovascular considerations, it’s genuinely a physician conversation.

Then the off-label tools that often work beautifully. Bupropion — an antidepressant that, unlike SSRIs, tends to raise desire, arousal, and orgasm — is frequently the answer when an antidepressant is what killed the libido in the first place. And that point deserves emphasis: if you’re on an SSRI and your desire vanished, that is a known, common, fixable effect, not a life sentence. Talk to your doctor about switching or adding something; don’t suffer it in silence.

And the hormonal options, individualized and supervised. Testosterone therapy for postmenopausal women — transdermal, dosed to normal premenopausal levels, properly monitored — has real evidence for improving desire, arousal, orgasm, and satisfying encounters, and is backed by consensus statements even though it isn’t yet formally FDA-approved for women in the US. For the dryness and pain of menopause, local vaginal estrogen, vaginal DHEA, and ospemifene are highly effective at restoring tissue health — and here is the part that matters most: fixing the pain often revives desire that was never actually gone, only guarding against hurt.

The through-line for all of it: these belong with a knowledgeable clinician — a gynecologist or sexual-medicine specialist — who evaluates you, weighs your history, and monitors you. Not an internet order. But the headline is pure hope: distressing low desire is a real medical condition with real treatments. You were failed by a system that never mentioned them — not by your own body.

Menopause is not the end of desire

Somewhere along the way, women were sold a lie: that menopause ends a sex life. I want to demolish that clearly.

What changes at menopause is largely mechanical and largely treatable. Falling estrogen thins and dries the genital tissue, which makes sex uncomfortable or painful. And here is the crucial chain: pain doesn’t only hurt — it teaches the body to avoid. Desire fades because your nervous system is protecting you from anticipated pain, not because wanting has died. Which means that fixing the tissue — with local estrogen, vaginal DHEA, or ospemifene — very often brings the desire back with it. When sex stops hurting, the desire that “disappeared” frequently walks right back in.

Beyond the tissue, the desire circuitry itself can be supported — testosterone where appropriate, and flibanserin, now approved for postmenopausal women under 65. And everything else in this guide applies with even more force after menopause: sleep, aerobic exercise for blood flow, pelvic floor training, good lubricants, mindful presence. Menopause is a transition, not a terminus. With the right combination, a great many women describe this chapter as freer and better — not worse. Find a menopause-literate clinician. They exist.

The whole plan, in order

If you want the map in one glance, here is the order I’d walk a patient through.

Start with the free foundations, and give them eight to twelve weeks: fix sleep first, add aerobic exercise three to five times a week, train the pelvic floor daily. Most women see meaningful gains from this layer alone. Then the accessible add-ons: good lubricant, a vibrator without embarrassment, solo exploration and honest communication, and mindfulness or sex therapy if stress is the driver — the evidence there is strong. Then, optionally, evidence-based supplements — ashwagandha for stress-driven issues, maca around menopause, tribulus for overall function — third-party tested, given a fair trial, cleared with your doctor, understood as modest help rather than miracles. And finally, if distress persists past about three months of real foundational work, the medical evaluation: a gynecologist or sexual-medicine specialist to rule out thyroid, anemia, diabetes, depression, and menopausal tissue changes, and to open up the prescription and hormonal options above.

Track the whole way with a simple journal — desire, ease of arousal and orgasm, satisfaction — because data beats guessing. And don’t wait through the layers if you have pain, sudden changes, or significant distress; those get seen now.

The truth under all of it

This was never about chasing some idealized, airbrushed “perfect” response. It’s about reclaiming pleasure and connection in the body you actually have — the one that carried you this far and is still, right now, capable of far more than medicine ever bothered to tell you.

Your sexuality is not a mystery, and it is not broken. It is a system. And now you have the map.

I’ve spent my life at the border between the body and the soul, and I’ve come to believe that pleasure is not a frivolous thing. It is one of the ways a body says it is alive, safe, and still reaching for another person. To reclaim it is not indulgence. It’s a kind of homecoming.

Most women improve. Patience, honesty, and good guidance do the rest.

Go be well. And go be alive in the body you have.

If this told you something no one else would, understand that it’s the free version of how I think — the real science, with the shame and the hype both stripped out. The deeper work lives on my Substack: the heart, longevity, desire, and how the body and the soul actually speak to one another, longer and quieter, with no algorithm deciding what you’re allowed to see. Subscribe for the full report — the honest conversation about your body that medicine keeps forgetting to have with you.

Share this with a woman who was told it was all in her head. It wasn’t.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

Minoxidil? It started as a blood-pressure pill. We noticed patients growing hair in places they didn’t ask for, and dermatology never looked back. Spironolactone — one of the best options for women — is a drug I still prescribe for heart failure and high blood pressure. Even finasteride touches the same hormonal machinery I think about every day.

So no, hair loss isn’t my clinical specialty. But I understand these molecules from the inside out. I know how they move through the body, what they do to blood pressure and potassium, and where the real risks hide versus where the internet just likes to panic.

And here’s what I’ve learned watching this from the cardiology chair: most people fail at hair loss not because the treatments don’t work, but because they start too late, quit too early, or chase gadgets instead of using the handful of things that are actually proven.

This is the no-nonsense guide I’d give a friend. Every major option, real dosage examples, and clear do’s and don’ts. Results take patience — usually three to twelve months. And one rule before we start: this is education, not a prescription. Get a real diagnosis and bloodwork before you touch any of it.

First: figure out why you’re losing it

Not all hair loss is the same, and treating the wrong cause is how people waste a year.

The most common culprit by far is androgenetic alopecia — pattern loss driven by genetics and your follicles’ sensitivity to DHT, a hormone that slowly shrinks them. But shedding can also come from stress (telogen effluvium), iron or vitamin D deficiency, thyroid disease, postpartum shifts, medications, or autoimmune conditions like alopecia areata.

Before spending a dollar on treatment, do this:

• See a dermatologist or trichologist. Rule out the reversible causes first.

• Get bloodwork: ferritin (iron stores — a huge one in women), vitamin D, thyroid panel, and hormones.

• Take baseline photos in consistent lighting. You cannot trust your memory on this; you can trust the camera.

• Move fast. A miniaturized follicle can be revived. A dead one cannot. Early is everything.

If your loss is sudden, patchy, or scarring — don’t wait. That needs urgent evaluation.

The only two drugs with full FDA approval

Everything else you’ll read about is used off-label. These two have earned the top-line stamp:

Topical minoxidil (Rogaine or generic) — over the counter, 2% or 5%, for both men and women. It works by widening blood vessels, extending the growth phase of the hair cycle, and likely nudging growth factors.

Dosage example: Men — 1 mL of 5% solution, or half a capful of foam, on a dry scalp twice daily. Women — the same, or once daily (2–5%). Foam tends to irritate less (less propylene glycol). Expect an alarming shed in weeks 2–8 — that’s the old hair making room, not a failure. Visible results in 3–6 months. Stop, and the gains reverse.

Oral finasteride 1 mg (Propecia) — men only, because it’s dangerous in pregnancy. It blocks the enzyme that makes scalp DHT, cutting it by 60–70%. On average, slightly stronger than topical minoxidil alone.

Dosage example: 1 mg once daily. Judge results at 6–12 months. Side effects are uncommon — sexual or mood changes in a small minority — and topical versions exist that lower whole-body exposure. Have an honest risk/benefit talk with your doctor rather than fearing it or dismissing it.

There’s also low-level laser therapy — FDA-cleared caps and combs, a modest add-on, roughly three sessions a week.

The heart-drug secret: low-dose oral minoxidil

This is where my world and the hair world overlap, and it’s the most important shift in the field in years.

We’ve prescribed oral minoxidil for blood pressure for decades. It turns out that at tiny doses — a fraction of the cardiac dose — it grows hair beautifully, with far better adherence than a messy topical you have to remember twice a day. For a lot of people it works as well or better than the liquid, simply because they actually take it.

It’s off-label and needs a prescription (often compounded to get the low doses exactly right). Here are the expert-consensus protocols from the international Delphi panel and clinical reviews:

• Women: start 0.625–1.25 mg once daily (a quarter or half of a 2.5 mg tablet). Maintenance usually 0.625–2.5 mg/day. Titrate up by 0.625–1.25 mg every 1–3 months if needed and tolerated.

• Men: start 1.25–2.5 mg once daily. Target 2.5–5 mg/day.

• Adolescents, low-weight, or cardiac-risk patients: start at the bottom (0.625 mg women, 1.25 mg men).

• Take it at night to blunt any dip in blood pressure.

Now the part I care about as a cardiologist — the monitoring, which too many people skip:

• Check a baseline blood pressure and heart rate. Recheck at 1–4 weeks and after dose increases, especially if you have low blood pressure, arrhythmia, or take other BP meds.

• Healthy patients don’t need routine labs or EKGs.

• The most common side effect is extra body or facial hair — dose-dependent, more common in women, and reversible if you lower the dose.

• Mild fluid retention (1–10%), a temporary shed, and rare fast heartbeat can happen. Serious cardiac events at these micro-doses are extremely rare.

• Don’t use it in pregnancy, uncontrolled hypertension, or pericardial disease. If you have heart risk factors, loop in a cardiologist. (Happy to be that voice in the room.)

Most people see something by month 2–6, with the real payoff later. Newer extended-release versions in trials are posting strong density gains with reassuring safety.

The DHT blockers — and going a step stronger

If pattern loss is DHT-driven, blocking DHT is the lever.

• Dutasteride — a stronger, dual-action blocker. Men: 0.5 mg daily, or 2–3 times a week. More effective than finasteride in head-to-head analyses, with a similar side-effect profile.

• Topical finasteride — 0.1–0.25% solution or spray, once or twice daily, with much lower absorption into the bloodstream.

The through-line in all the best data: combination beats monotherapy. A DHT blocker plus a growth stimulator plus a simple adjunct will always outperform any single hero product.

Women: this is a different game

Female hair loss deserves its own plan, not a hand-me-down of the male protocol.

• Minoxidil is first-line — topical, or low-dose oral.

• Spironolactone (my old heart-and-blood-pressure friend) is excellent when there’s androgen excess or PCOS. Start 25–50 mg daily and titrate to 50–200 mg, watching potassium and kidney function. Bonus: its mild diuretic effect offsets the fluid retention oral minoxidil can cause, which is why the two pair so well.

• Oral finasteride is generally avoided before menopause; spironolactone is preferred, and strict contraception is non-negotiable on any anti-androgen because of birth-defect risk.

• Post-menopausal women get more anti-androgen flexibility.

• A hormonal workup matters more here than in men. Don’t skip it.

The cheap adjuncts that punch way above their price

You don’t need a boutique clinic for these, and the evidence is real.

Ketoconazole shampoo (1% or 2%, e.g., Nizoral) is one of the best-supported things on any drugstore shelf. It’s a powerful antifungal that calms the scalp inflammation tied to dandruff and seborrheic dermatitis, and it mildly blocks DHT locally — lowering scalp DHT by roughly 12–16%. In studies, including one head-to-head with 2% minoxidil, it improved density and shaft thickness as an adjunct.

How to use it: Lather the whole scalp, leave it on 3–5 minutes, rinse. Two to three times a week when you’re actively treating, once a week for maintenance. Alternate with your normal shampoo. Barely any gets into your bloodstream.

Microneedling — 1 to 1.5 mm depth, once a week or every couple of weeks. On its own it’s fine; combined with minoxidil it’s a multiplier, with studies showing several-fold higher hair counts. Keep the device clean and don’t overdo it.

Rosemary oil — one randomized trial found it non-inferior to 2% minoxidil. Dilute it in a carrier oil and apply a few times a week. Not magic, but a legitimate entry point.

Caffeine shampoos, topical melatonin (mostly European data), and plain consistent scalp massage round out the supportive tier.

Procedures, when you want volume back

• PRP injections — your own growth factors, 3–4 monthly sessions then maintenance. Best as an adjunct.

• Hair transplant — FUE (tiny dot scars, faster recovery, preferred for most) or FUT (strip method, more grafts per session, a linear scar). With a skilled surgeon, 90–95% of grafts survive; 1,500–4,000+ per session; full results at 12–18 months. Critical: keep taking your meds afterward to protect the hair you were born with, and only use board-certified, experienced surgeons.

Supplements: the honest truth

I’ll be blunt, because your wallet deserves it. Supplements mostly help when they’re fixing a genuine deficiency — not as blanket growth boosters.

• Iron/ferritin, vitamin D, zinc — worth correcting if your labs are low.

• Pumpkin seed oil (~400 mg), saw palmetto (320 mg), tocotrienols, and some multi-ingredient formulas (like Nutrafol) showed modest gains in a few trials.

• Biotin — rarely useful unless you’re deficient, and high doses can distort your lab results.

Test first. Don’t megadose on faith.

The do’s and don’ts, in one screenshot

DO:

• Get diagnosed, get baseline labs, take photos.

• Start an evidence-based combo early. Men: finasteride 1 mg + minoxidil (5% topical or 2.5 mg oral) + ketoconazole 2–3×/week + weekly microneedling. Women: minoxidil (0.625–1.25 mg oral or topical) ± spironolactone 25–50 mg + ketoconazole.

• Titrate oral minoxidil slowly and check your blood pressure early.

• Commit a full 6–12 months before judging anything.

• Protect the basics: protein, sleep, stress, scalp health.

• Layer procedures (microneedling, PRP, laser) for synergy.

DON’T:

• Wait, hoping it “stops on its own.” It usually doesn’t.

• Rely on biotin, onion juice, castor oil, or the remedy that went viral last week.

• Wear tight, pulling hairstyles or ignore an inflamed scalp.

• Panic and quit during the early minoxidil shed.

• Self-dose high anti-androgens or ignore pregnancy risk.

• Buy every new clinic gadget without evidence behind it.

• Assume “natural” means safer or better — that belief delays real care every day.

The bottom line

For most pattern hair loss, the highest-return path hasn’t changed: start early, combine treatments, and stay consistent. Minoxidil — topical or precisely dosed oral — plus the right DHT blocker, plus cheap adjuncts like ketoconazole and microneedling. Procedures and transplants shine when you need real volume back. Supplements play a supporting role, at best.

I’ve watched people spend years and thousands chasing the next miracle while walking past the boring, proven protocol that would have worked. Your future density is decided by what you do now — not by the perfect plan you keep meaning to start.

Diagnose it. Build the foundation. Give it a year.

The follicles you save are the ones you act on today.

This is educational, not personalized medical advice. Discuss every option, risk, and monitoring plan with your own physician.

Blessings,

Afshine “Ash” Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

🏅 Castle-Connolly Nationwide Top Doctor (since 2008) 🌟 Los Angeles Magazine Super Doctor (since 2010) 🇺🇸 LA Style Magazine Top 100 Doctors in America (2024)

📬 Subscribe to my newsletter: substack.com/@afshineemrani 📚 Explore my books: Amazon Author Profile

Two medicines were built to lower blood sugar. They keep quietly saving lives instead — and a cardiologist explains what that really means for you

Some of the most important discoveries in medicine were never the thing we were looking for.

Penicillin was a contaminated petri dish. The pacemaker began as a wiring mistake. And right now, in real time, we are living through another one — except this time the accident isn’t a mold or a miswired circuit. It’s two entire classes of drugs, designed to do one modest job, that turned out to do something their inventors never promised:

They help people live longer.

I have spent twenty-five years as a cardiologist watching the longevity world chase immortality through mouse studies, supplement stacks, and molecules that look dazzling in a petri dish and vanish in a human being. And the whole time, the two drugs with the strongest evidence for extending healthy human life were sitting in the diabetes aisle, wearing name tags that said something else entirely.

Let me tell you what they are, what the data actually shows, and — because I am a physician and not a salesman — exactly where the hype outruns the truth.

The difference that matters: mouse hope vs. human proof

First, a rule I want you to carry through this entire essay, because it separates real medicine from beautiful fiction.

Almost everything marketed as a “longevity compound” rests on one of two thin foundations: it made mice live longer, or it correlated with something good in an observational study. Rapamycin. Metformin. Acarbose. Lithium. Fascinating molecules, every one. But their human longevity evidence is weak, indirect, or purely preclinical. They are promises, not proof.

The two drugs I’m about to describe are different in kind, not degree. They earned their place at the top of the evidence rankings the hard way — through enormous randomized controlled trials measuring the only endpoints that can’t be spun: death, heart failure, kidney failure. Tens of thousands of real human beings, followed for years, with a placebo group to keep everyone honest.

That is the gold standard. And these two cleared it while no one was looking for longevity at all.

Drug class #1: SGLT2 inhibitors — the calorie-restriction mimic in a pill

You may know them by their names: empagliflozin, dapagliflozin, canagliflozin. They were built for one purpose — to lower blood sugar in type 2 diabetes — and they do it through one of the strangest mechanisms in pharmacology.

They make you urinate out your sugar.

By blocking a transporter in the kidney, an SGLT2 inhibitor causes you to spill roughly 60 to 90 grams of glucose into your urine every day. That’s 240 to 360 calories of sugar, flushed away. In effect, the drug creates a mild, continuous caloric-restriction and light-ketosis state — and caloric restriction is the single most reproducible life-extending intervention in the history of biology.

But here’s where it stops being interesting and starts being astonishing. When researchers ran the big outcome trials — EMPA-REG, DECLARE, DAPA-HF, EMPEROR-Reduced, DAPA-CKD, EMPA-KIDNEY — they found something no one had promised:

• Pooled analyses show around a 14% relative reduction in all-cause mortality in the populations studied. Not sugar numbers. Death.

• Sharp reductions in cardiovascular death, heart-failure hospitalizations, and the progression of chronic kidney disease.

• And — this is the part that rewrote guidelines — those benefits held up in people who don’t even have diabetes. In several of the landmark heart-failure and kidney trials, a third to half of the participants weren’t diabetic at all. The drug was protecting hearts and kidneys through some pathway that had nothing to do with blood sugar.

So cardiologists like me started asking the obvious question: if the benefit isn’t really about glucose, what is it about?

Why it looks like aging itself

The mechanisms that emerged read like a checklist of the biology of aging:

AMPK activation — the cellular “energy sensor” that also gets switched on by exercise and fasting, and that governs how cells repair and recycle themselves. Mild ketosis, which appears to be a cleaner, more efficient fuel for a stressed heart. Improved mitochondrial function — better power plants in your cells. Reduced systemic inflammation, including the low-grade “inflammaging” that smolders under nearly every age-related disease. Upregulated autophagy — the cell’s self-cleaning process, hauling out damaged parts before they accumulate. There are even early signals of senolytic activity: helping the immune system clear out “senescent” cells, the aged, dysfunctional cells that linger and poison the tissue around them. And in one small trial, a signal of telomere lengthening — the protective caps on our chromosomes that normally fray with time.

Male mice on these drugs live longer. The human healthspan trials — the ones designed specifically to test aging as the endpoint — are still pending. But you do not need to wait for those to appreciate the point: we already have hard mortality data in humans. That is more than almost any “longevity drug” on earth can say.

Drug class #2: GLP-1 receptor agonists — the ones you’ve already heard about

Semaglutide. Liraglutide. Tirzepatide. Ozempic, Wegovy, Mounjaro. You cannot open a phone without meeting them. Everyone knows them as weight-loss drugs, and before that, diabetes drugs. Almost no one is talking about the part that matters most to a cardiologist.

SELECT was the trial that changed the conversation. It took people who were overweight or obese and had established cardiovascular disease — but did not have diabetes — and gave them semaglutide or placebo. The result: roughly a 20% reduction in major adverse cardiovascular events — heart attack, stroke, cardiovascular death. In a population that wasn’t taking it for diabetes at all.

FLOW looked at the kidneys, in people with type 2 diabetes and chronic kidney disease, and found about a 24% reduction in major kidney events, along with mortality signals pointing the right way.

Zoom out to the broader meta-analyses and the pattern holds: reductions in cardiovascular events on the order of 13 to 14%, fewer strokes, fewer heart-failure hospitalizations, lower all-cause death in high-risk groups, and measurable kidney protection. And now the frontier signals — the ones still early, still small, but worth watching: lower dementia risk in some cohorts, and slower “epigenetic aging clocks” in early studies, including one HIV cohort where a biological-aging measure slowed by roughly 9%.

Crucially, a meaningful share of the cardiovascular benefit appears to be partly independent of the weight loss itself. Something else protective is happening — likely the anti-inflammatory and direct vascular effects — beyond simply carrying fewer pounds.

Now the part the influencers skip: the honest risks

Here is where I have to be a doctor, because the internet will sell you the upside and bury the fine print, and my job is the opposite.

Muscle loss is real, and it’s the big one. GLP-1 drugs cause weight loss, and a portion of what’s lost is not fat — it’s muscle. For an older adult, muscle is not vanity; it is survival. It’s your metabolism, your balance, your defense against a fall that starts the last chapter of too many lives. Losing weight while losing muscle can trade one aging problem for a worse one. This is why I will not discuss these drugs without saying, in the same breath: adequate protein and resistance training are not optional add-ons. They are part of the prescription.

Gastrointestinal effects — nausea, and in some people significant slowing of the gut — are common, especially early.

Rare but serious signals deserve honesty: pancreatitis, and a debated but real ongoing discussion around NAION, a form of “eye stroke,” where the evidence is still being sorted out. I raise these not to frighten you but because you deserve the whole ledger.

And the quiet structural problem: for most people, these are lifelong drugs. Stop them, and the weight — and often the metabolic risk — tends to return. That is a very different life decision than a short course of anything, and it deserves to be made with clear eyes.

For SGLT2 inhibitors the risk profile is different and generally gentler, but not zero — a specific type of dehydration, genital yeast infections from all that urinary sugar, and a rare metabolic complication that a knowledgeable physician watches for.

None of this cancels the benefits. It contextualizes them. A drug can extend life and still demand respect.

Head to head: which does what

If you want the cardiologist’s cheat sheet:

SGLT2 inhibitors shine brightest on heart failure and on the broad protection of the kidneys — and they carry the strongest all-cause mortality signal of the two. If I had to rank them by the weight of hard human endpoints, they sit at number one.

GLP-1 agonists shine on atherosclerotic events and stroke, and of course on the metabolic transformation that comes with substantial weight loss. Number two — an extraordinary number two.

And the most tantalizing data of all suggests the two classes may be additive — that using both, in the right person, could project more years free of cardiovascular and kidney events than either alone. We are only beginning to map that combination.

What I actually want you to take from this

Let me be very clear about what this essay is and is not.

It is not a prescription. It is not permission to order anything off the internet, and it is emphatically not a suggestion that healthy people should reach for powerful metabolic drugs as a shortcut to living forever. These medicines were studied in specific populations — people with diabetes, established heart disease, obesity, kidney disease — and that is where the evidence lives. The person they help most is not the biohacker chasing an extra decade. It’s the ordinary patient sitting across from me with a struggling heart or a failing kidney, whose life these drugs can measurably lengthen.

Whether they belong in your life is a decision for you and a physician who knows your history, checks your labs, watches for the risks I listed, and treats you as a whole human being rather than a set of numbers to optimize. The longevity clinics selling these as lifestyle enhancements are running ahead of the evidence. The cardiologists prescribing them to the right patients are practicing some of the best medicine of our era. The difference between those two things is everything.

But step back and feel the largeness of what’s happening here. We set out to lower blood sugar, and we stumbled into medicines that protect the heart, guard the kidneys, cool the fires of inflammation, and — in the populations we’ve studied — hold death itself at a small but real distance. We were looking for a better glucose number and found, by accident, a longer life.

The last word

I have stood at more bedsides than I can count, and I have learned that the goal of medicine was never simply more time. A longer life spent afraid, sedentary, and disconnected is not the prize. The prize is more good years — more mornings with the people you love, more strength in your legs, more clarity behind your eyes, more of you.

These accidental drugs are a gift, but they are not the point. They buy time. What you do with the time is the actual work — the walking, the eating well, the sleeping, the loving, the staying connected, the small daily faithfulness to a body you were only ever loaned.

The pill can hold death at a distance. Only you can fill the years it gives back.

So talk to your doctor. Read the whole ledger. And then go live in a way that would make the extra decade worth having.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

You can hold your face together in a boardroom. You can smile through a diagnosis, a funeral, a marriage quietly coming apart. The body is a diplomat almost everywhere it goes.

But not in bed. In bed, the body finally tells the truth — about your hormones, your nerves, your blood vessels, and, though almost no one is listening, about your heart.

I have practiced cardiology for twenty-five years. I have watched the entire architecture of a man’s health announce itself, first and most honestly, in the one place he was least prepared to hear it. And I have come to believe that “sexmaxing” — the internet’s new obsession with optimizing sexual function — is asking the right question with the wrong map.

Because the men chasing a better night are ignoring the most sensitive early-warning system in all of medicine. It has been running the whole time. They simply never learned to read it.

This is the long version — everything I’d tell you if you were sitting across from me and we had the afternoon. Let me teach you to read your own body.

Part I — The mistake almost everyone makes

We talk about sex as if it were a single event that either works or doesn’t. On or off. Hard or soft. Pass or fail.

It isn’t. An erection — real sexual function — is four separate systems firing in sequence, each with its own biology, each capable of failing for completely different reasons:

Desire — the brain. The do I even want this. Arousal — the nervous system. The wiring that carries the signal from mind to body. Blood flow — the vessels. The plumbing that makes the mechanics possible. Orgasm and bonding — the hormones. The intensity of the finish, and the closeness after.

Break any one link and the entire chain feels broken. But the reason it broke — and the fix — lives in a different system each time. Treat the wrong one and you’ll do everything “right” and still feel like a stranger in your own body.

Hold that four-part map in your head. Almost everything that follows is an argument that the little blue pill fixes exactly one of them and quietly markets itself as the whole answer.

Part II — Viagra solved a quarter of the problem, and sold it as the whole thing

Viagra and Cialis are genuinely great drugs. I prescribe them. They belong to a class called PDE5 inhibitors, and their mechanism is elegant: they block an enzyme that would otherwise break down the chemical signal that dilates blood vessels. Stop the breakdown, and the signal to open stays switched on. The result is more flow, on demand. It is one of the great pharmacologic discoveries of the last century.

But notice where it acts. Blood flow. Step three. The plumbing. That is all it touches.

If your problem is desire, or arousal, or the hollow, disconnected quality of the finish, a PDE5 pill does nothing for you. It floods a house whose lights were never turned on. This is why so many men take the pill, watch the hydraulics work perfectly — and still feel nothing. No hunger. No pull. No reason to cross the room.

That is not a broken drug, and it is not a broken man. It is a category error. You treated a brain problem with a blood-vessel tool and then blamed yourself when the emptiness didn’t lift.

The interesting science — the actual frontier — is all upstream of the plumbing. There are three frontiers, and no pill on your nightstand has reached any of them.

Part III — The three frontiers

1. Kisspeptin — the master switch

Deep at the top of your hormonal cascade sits a molecule that functions like the master switch for the entire sexual system. It gives the command that begins the whole program — long before a single blood vessel is involved. Its name is kisspeptin.

For years it was a fertility-lab curiosity, known mostly as the trigger that ignites puberty and drives the reproductive hormones. Endocrinologists cared; nobody else did. Then researchers asked a sharper question: what if the problem for so many people isn’t the plumbing at all, but the command that’s supposed to switch everything on?

So they ran the trial. In 2023, a research team gave kisspeptin to men with low sexual desire — not classic erectile dysfunction, but the harder, quieter, more shameful problem of simply not wanting. The results turned heads. On functional brain imaging, kisspeptin lit up the brain’s entire sexual-processing network — the circuits that assign meaning and generate pull. Penile arousal response climbed by more than half — up to 56% — over placebo. And the men reported feeling more, not merely functioning more. A parallel trial in women with low desire showed the same kind of thing: modulation of the brain’s sexual and attraction circuitry, and women reporting they felt more drawn, less averse. Both trials were well tolerated.

Sit with what that means. Desire — the thing we always dismissed as mood, psychology, “just how you feel” — behaved like a real, measurable, reachable target. A switch you could actually find and flip. That is not a small upgrade to Viagra. That is a different category of medicine, and it is still early enough to feel like the opening chapter of something. It is research, not a product on a pharmacy shelf — but it is the strongest signal we have ever had that “I just don’t want it anymore” has a genuine biological address.

2. The melanocortin pathway — where wanting itself is born

Here is a truth that quietly haunts a great many men, and almost no one explains it kindly:

You can be fully capable in bed and feel no hunger for it at all. Everything works. You don’t care. And you lie there wondering what is wrong with you.

Nothing is wrong with you. Deep in the hypothalamus runs a circuit called the melanocortin pathway, and its entire job is to generate wanting — not the mechanical ability, but the pull, the reaching-toward, the appetite that makes you cross the room in the first place. It works by nudging the brain’s dopamine and reward machinery. Desire and function are two different machines. You can own a flawless engine and a dead ignition.

This is precisely the circuit Viagra never touches. PDE5 drugs work in the vessels; this works in the brain’s motivation system, and the two do not overlap. That single fact explains one of the most common and most private disappointments in men’s health: the pill worked, and the wanting still wasn’t there.

Modern research has produced molecules that act on this melanocortin pathway directly — creating arousal and desire from the top down, in the brain, rather than routing through the bloodstream. The first of them reached the market having been studied in women whose desire had gone silent, and there is real off-label experience in men, including men who never responded to PDE5 drugs at all. It comes with real trade-offs — flushing and nausea chief among them — which is exactly why it belongs in the hands of a physician and not a group chat. But the headline isn’t any single drug. The headline is that wanting is finally something science can aim at.

3. Oxytocin — the most underrated molecule in sex

Everyone calls oxytocin the “cuddle hormone,” and in doing so they insult it. That nickname makes it sound optional — soft, a garnish, a nice-to-have.

It is none of those things. Oxytocin surges at the moment of orgasm. It drives the intensity of the peak itself, and then the wave of disarmed closeness that follows — the deep, tethered, unguarded feeling after real intimacy. It is the molecular difference between a transaction and a connection, between sex that relieves one person and sex that binds two. Research on intranasal oxytocin in couples found greater orgasm intensity and greater contentment afterward, with some of the strongest effects in men. The effect is modest, but it is real, and it points at something large: the finish and the bond are their own system, with their own chemistry, that you can actually influence.

And here the blue pill has nothing at all to offer. It manages friction and ignores meaning entirely. We optimized the mechanics of sex and abandoned the part that actually makes it matter over the course of a life.

There is a cardiologist’s footnote here too, and it’s not small: oxytocin lowers stress and blood pressure and buffers the heart against chronic strain. Connection is not merely good for your relationship. It is measurably good for the organ keeping you alive. Intimacy is cardiac medicine we almost never think to prescribe.

Part IV — The whole map, in one place

Before I turn to the part I actually came to tell you, let me lay the board out cleanly, because this is the picture I wish every man had before he ever swallowed his first pill:

• Desire → kisspeptin territory. The master switch at the top of the cascade.

• Wanting / arousal → melanocortin territory. The circuit that generates hunger itself.

• Blood flow → PDE5 territory. Viagra, Cialis — the one part they own, and the one wired straight into your heart.

• Orgasm and bonding → oxytocin territory. The peak and the afterglow.

Four systems. Four different machines. One drug class that handles a single quarter of the problem while presenting itself as the entire answer.

Learn all four and you stop misdiagnosing yourself. You stop treating a desire problem with a plumbing pill and wondering why you still feel empty. You get better — and gentler with yourself — in every one of them.

And you never forget that System Three is doing double duty. Because it isn’t only the plumbing of sex. It is the early-warning system for your heart.

Part V — The turn: your erection is a stress test

You could stop reading here and be better informed than most men alive about the science of desire. But I am a cardiologist, and I would be failing you if I let you leave with only that.

Here is what keeps me up at night:

Your erection is a stress test. You take it constantly, for free, with no treadmill and no electrodes. You have simply never read the result.

Let me give you the number almost no man has ever heard. The arteries that feed an erection are roughly one to two millimeters across. The coronary arteries feeding your heart are three to four millimeters. Same body. Same blood. Same disease process when plaque begins to build.

But plaque clogs the narrow pipes first. It is simple physics applied to your own anatomy.

The tiny penile arteries choke on buildup years before the larger coronary ones show a single symptom. Which means erectile decline is often the very first visible sign of vascular disease anywhere in the body — appearing, on average, three to five years before a heart attack.

Read that again. Three to five years of advance warning. A head start most of my cardiac patients would trade almost anything to have had. And most men spend that priceless window embarrassed, hiding, or quietly ordering pills off the internet — silencing the alarm instead of answering the door.

Because that is what it is. A door. Your body knows you will ignore fatigue. It knows you will wave off “I’m just getting older.” So it delivers the message somewhere you cannot possibly miss it, at the one door a man will actually open. That is not a malfunction. That is mercy — if you are willing to receive it.

One organ, fingertips to heart

There is a reason all of this connects, and its name is the endothelium — the single-cell lining inside every blood vessel you own. One continuous sheet, unbroken, running from the tips of your fingers to the chambers of your heart to the tissue that makes an erection possible. It weighs more than your liver. It is not passive plumbing; it actively governs how vessels open, relax, and stay clean.

And it is one organ. So when it begins to fail — from high blood pressure, high blood sugar, smoking, inflammation, ruined sleep — it does not fail in one isolated spot. It fails everywhere at once. The whole lining stiffens and misfires together. The bedroom is simply where a man notices first, because the penile vessels are the smallest and least forgiving, the tissue with the least margin for error.

Erectile decline, then, is not an isolated embarrassment. It is your endothelium sending up its first flare — a live readout of the exact tissue that determines whether you have a heart attack. And here is the hopeful part: the endothelium heals. It responds, sometimes remarkably fast, to the unglamorous things. Fix the lining and you repair both rooms at once — the bedroom and the chest — because they were never separate to begin with.

Part VI — What happens in my office

Let me tell you how this actually plays out, because no advertisement will ever show it to you.

A man comes to me for his sex life. He is embarrassed. He has rehearsed the conversation in the car. He wants a prescription and a quick exit.

I do not reach for the prescription pad. I reach for his numbers. Blood pressure. Cholesterol. Blood sugar. Sleep. Stress. Family history. Because he did not actually bring me a bedroom complaint. He brought me a vascular one — he just doesn’t know it yet.

I refuse to treat the erection in isolation, and here is why. The vessels that failed in the bedroom are made of the same lining, fed by the same blood, threatened by the same plaque as the vessels feeding his heart — and the small ones always fail first. His symptom is a window. It would be negligent to paper over it with a pill and send him home.

So every so often, I find it. The blood pressure that has been quietly cooking his arteries for a decade. The cholesterol nobody flagged. The early coronary disease with a three-to-five-year fuse already lit. I find the thing that would have dropped him on a treadmill, or in his sleep, or on a Tuesday afternoon — because his erection knocked on the only door he would answer.

And then comes the moment I have never gotten used to. He came in for his sex life. He leaves having had his life extended. Sometimes he understands what just happened. Sometimes he never fully does. The bedroom saved him, and he thought he was there for something else entirely.

If you are that man — rehearsing the awkward conversation in the car right now — come in anyway. And when you do, do not ask only for the pill. Ask for the workup. Ask what your erection is telling you about your heart. That is the question that saves lives. I have watched it save them.

Part VII — How to actually read the report

Stop treating your sex life as a performance to pass or fail. Start reading it as a report your body is filing on itself, in real time, in a language you were never taught. Once you can read it, everything changes.

Desire that has gone quiet is a brain signal. It can mean hormones, dopamine, stress, sleep debt, a medication, or the early vascular changes that starve a brain of good blood flow. “I just don’t want it anymore” is data, not a verdict. It deserves a workup, not a shrug.

Arousal that won’t come is a nervous-system signal. The wiring between brain and body isn’t firing cleanly. Anxiety, nerve health, blood sugar, and circulation all live here. It is rarely “all in your head” in the cruel way people imply. It is in the wiring — and wiring can be checked.

An erection that fades is a vascular signal — and this is the loudest one. It is often the earliest warning your heart will ever hand you. This is the signal you never, ever ignore.

A finish that feels hollow — no intensity, no closeness after — is a bonding signal. That is the oxytocin layer, the part that decides whether sex connects you to someone or merely discharges tension. A lifetime of intimacy is built there, not on hardness.

Four signals. Four systems. One body, telling you the truth in the only room where it can’t lie.

Part VIII — What actually helps

This is the part the internet gets dangerously wrong. It will sell you a vial and a dosing protocol and call it optimization. I have spent a quarter century watching what that road does to hearts. Here are the levers with real evidence behind them — in the order I would pull them, the order I would give my own brother.

Move your body. This is the most underrated sexual drug on earth. Exercise repairs the endothelium directly, raises nitric oxide, lowers blood pressure, sharpens insulin sensitivity, and lifts testosterone and mood. Men who train regularly have measurably lower rates of erectile dysfunction. No pill does all of that at once.

Sleep — and get tested for apnea. Most of your testosterone is manufactured during deep sleep; wreck the sleep and you wreck the hormone. Untreated sleep apnea quietly destroys both erections and hearts, hammering the vessels all night long. If you snore, wake exhausted, and your desire has vanished, that is not a coincidence. Get a sleep study.

Eat like your vessels depend on it — because they do. A Mediterranean pattern is one of the few eating styles actually shown to improve erectile function and cut cardiac risk: olive oil, fish, plants, nuts; far less sugar and processed junk. Nitric oxide — the very molecule Viagra’s mechanism depends on — is built by a well-fed, well-exercised endothelium. Feed the machine.

Supplements with real mechanism, not magic. L-citrulline (in the range of 3–6 grams) raises nitric oxide and mildly improves blood flow through the same pathway as the pills, more gently; L-arginine works alongside it. These are legitimate and food-adjacent. Skip the “male enhancement” blends — they are mostly caffeine, hope, and occasionally hidden pharmaceuticals that can be dangerous precisely because you don’t know they’re there.

The pills — used intelligently, not secretly. Tadalafil is the most useful PDE5 inhibitor for many men because of its long duration, and a daily low dose also eases prostate and urinary symptoms, with genuine interest in what steady vascular support does over time. But the rule is absolute: a PDE5 pill should be a decision made with a physician who has checked your heart first — never a thing you order around the workup. The pill can mask the very warning this entire essay is asking you to hear.

The honest order of operations: get evaluated → fix sleep, movement, diet, blood pressure, and blood sugar → add the food-based support → then, only if needed, the right medication under real guidance. That sequence treats the whole man. It also happens to protect the one organ trying to keep him alive.

Everything above belongs with a doctor who understands the whole system, who draws baseline labs and checks your blood pressure, who is treating a man and not a symptom. The newer frontiers — the peptides and central agonists everyone is whispering about online — are real science, but they carry real cardiovascular effects, real interactions, and in some cases no approval for this use at all. They are not something to source from a stranger and inject on a hunch. This essay is education, not a prescription, and the internet is not your cardiologist.

Part IX — The last thing, and the real thing

I have spent a lifetime standing at the border between the body and the soul, and I have never found that border as sharp as we pretend it is.

The bedroom is the most honest room in your life not only because the vessels can’t fake it, but because intimacy strips away the performance we wear everywhere else. It asks the truest questions a body can ask: Do I want. Can I connect. Am I well. Am I still here.

When the answer falters, the temptation is to name it failure and reach for the fastest fix — a pill, a vial, a silence. But your body is not failing you when it speaks. It is loving you in the only language it has. The fading erection is not your enemy. It may be the most faithful messenger you will ever receive, carrying — years in advance — the one piece of news that could save your life.

So optimize. Chase the upgrade. Learn all four systems; it will make you better, and more merciful with yourself, in every one of them.

But read the whole report. Because the most powerful thing your body does in the dark is not perform.

It is warn you. It is tell you the truth. It is knock, patiently, on the only door you will answer — and wait to see whether you will finally open it.

Open it.

If this changed how you see your own body, understand that it is only the free sample. The deeper work — the science of the heart, longevity, desire, and how the body and the soul actually speak to each other — lives here, longer and quieter, with no algorithm deciding what you’re allowed to see. Subscribe for the full report, not just the headlines.

And one more thing. Every word above was written about men, because that is where the questions came in. But the science of desire, arousal, bonding, and vascular health is every bit as real in women — and their cardiac risk is more underdiagnosed, not less. The kisspeptin trials ran in women too. So did the desire research. So does the warning. If you want the version of this written for you — the desire science, the arousal biology, the bonding chemistry, and the cardiac signs medicine keeps missing in women specifically — tell me in the comments. If enough of you ask, that is the next essay.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

“I thought it was just protein powder.”

It was not protein powder. It was a vial of research-grade peptide, ordered online, shipped in a plastic bag with a label reading “for research use only — not for human consumption,” reconstituted with bacteriostatic water bought from the same website, and injected into her sixteen-year-old son’s shoulder in his bedroom.

He is fine. Many are not.

There are documented cases of teenagers developing infections from contaminated vials severe enough to require skin grafts. There have been amputations. There have been cardiac events, severe allergic reactions, and hormonal disruption in young people whose bodies were still under construction.

Some of these kids started at twelve or thirteen.

I am a cardiologist. I do not treat many adolescents. But I treat the adults those adolescents become, and I have spent enough time reading this literature and hearing from worried parents that I think this needs to be said plainly, by a physician, in language a teenager will actually read.

So this article is written for two audiences at once.

Parents: here is what is happening, what to look for, and how to have the conversation.

And if you’re the teenager who found this yourself — because you’re doing your own research before you buy something, which is genuinely smart — I want to talk to you directly too. Not to lecture. To tell you what these compounds actually do inside a body your age, and what will get you the result you’re actually after, faster and permanently.

PART ONE: WHAT IS ACTUALLY HAPPENING

Teenagers are buying compounds like BPC-157, TB-500, CJC-1295, ipamorelin, and various “recovery” or growth stacks — from websites, from Instagram and Discord sellers, and from people at their gym.

They are mixing them at home. They are injecting them. And they are doing it on the basis of social media claims about faster recovery, more muscle, better skin, and “anti-aging.”

In a fifteen-year-old.

Here is what is absent from that entire chain: no physician. No baseline bloodwork. No monitoring. No sterile technique training. No quality control. No dosing standard. No adverse event reporting. And no idea whether the substance in the vial is even the substance on the label.

Over forty percent of gray-market peptide samples fail basic purity or dose testing. Wrong content. Under-dosed. Misidentified entirely. Bacterial endotoxins. Heavy metals.

And that “not for human consumption” label? It is not a warning about quality. It is legal protection for the seller — a phrase that lets a company sell an injectable substance without meeting any pharmaceutical standard whatsoever. It works. That is precisely why every one of these vendors uses it.

PART TWO: WHY A TEENAGE BODY IS THE WORST POSSIBLE PLACE FOR THIS

This is the section I most want a teenager to read, because it is not a moral argument. It is physiology.

During adolescence, your body is still under construction. And that is not a figure of speech — specific, irreversible construction is happening on a schedule.

Your growth plates are still open. These are zones of cartilage at the ends of your long bones where growth actually occurs. When they close, you stop growing. Permanently. There is no reopening them.

Your natural growth hormone and IGF-1 levels are already at the highest they will ever be in your life. Higher than any adult you know. Higher than the professional athletes you follow.

Think about that for a moment. You are already running the most powerful anabolic program your body will ever run. There is no deficiency to correct. There is no missing signal to supply. You are, hormonally, at peak.

And your reproductive and hormonal systems are still calibrating — the feedback loops that will govern your testosterone, your fertility, and your metabolism for the rest of your life are being set right now.

Introducing external compounds that push growth, healing, or hormone signaling into that system is not optimization. It is interference with a process that is already running correctly and cannot be re-run.

What can go wrong

Disrupted puberty timing.

Premature closure of the growth plates — which means you end up shorter than you would have been. Permanently. I want to state that as bluntly as possible, because for a teenager chasing physical development, this is the specific irony: you can take something to look bigger and end up shorter for the rest of your life.

Insulin resistance and blood sugar dysregulation. Growth hormone pathways and insulin pathways are intertwined; pushing one affects the other.

Fluid retention, joint problems, and cardiovascular strain.

Unknown effects on mood and brain chemistry during the years your brain is undergoing its most significant remodeling since infancy.

Immune reactions — your immune system can recognize these molecules as foreign and mount a response, and the impurities in gray-market product make that considerably more likely.

And the honest summary: there is essentially no long-term safety data in healthy young people. Nobody knows what happens at thirty-five to someone who started injecting these at fourteen. Not because it’s fine. Because nobody has studied it, and nobody will for decades.

PART THREE: “BUT PEPTIDES AREN’T STEROIDS”

This is the argument I see most often, and it contains a grain of truth wrapped around a serious error.

What’s true: peptides are different molecules operating through different pathways, and many do not suppress natural testosterone the way anabolic steroids do. That is a real distinction.

What’s false: the conclusion that this makes them safe for a developing body.

Let me lay out what we know about steroids in teenagers, because we have decades of data there:

Stunted height from premature growth plate closure. Testicular shrinkage, reduced sperm count, and fertility problems in boys. Breast tissue development in boys. Facial hair, voice deepening, and menstrual disruption in girls. Severe acne. Hair loss. Liver damage and liver tumors. High blood pressure and adverse cholesterol changes that raise cardiac risk decades later. Mood swings, aggression, and depression. And dependency.

Steroid use among high school students remains relatively low — under one percent in recent surveys — but the documented costs are severe and frequently permanent.

Now here is the reasoning error.

We know steroids are dangerous in teenagers because they have been used long enough for the damage to be documented. The evidence exists because the harm accumulated over decades and researchers went looking for it.

Peptides have not been used long enough or studied enough in adolescents for that evidence to exist.

Absence of evidence is not evidence of safety. It is simply absence.

And peptides still interfere with growth signaling, healing pathways, and hormone regulation in a body that has not finished developing. Add contamination risk and dosing errors from unregulated product, and treating them as “the safer new steroids” is a genuine mistake.

Both are shortcuts during the exact years your body is supposed to finish building itself.

PART FOUR: WHO THESE ARE ACTUALLY FOR

There is a legitimate conversation happening about certain peptides in adults — and I want to be fair about it, because dismissing it entirely is neither honest nor persuasive.

Adults in their forties, fifties, and beyond who already have accumulated damage — degenerative joint disease, cardiovascular disease, metabolic dysfunction, poor healing capacity, age-related hormonal decline — are exploring some of these compounds under medical supervision. The FDA is currently considering pathways for lawful compounding of several.

That is a completely different situation.

Those adults have something to restore. Declining function. Impaired healing. Measurable deficiency.

A healthy fifteen-year-old has none of that. Their natural systems are running at maximum capacity. Their healing is the fastest it will ever be. Their hormonal output is at peak.

There is nothing to fix. There is only something to disrupt.

PART FIVE: WHAT ACTUALLY WORKS — AND WORKS BETTER

Now the part I most want the teenager reading this to take seriously, because I am not going to spend two thousand words saying no and then offer nothing.

Here is the honest truth from someone who has studied human physiology for twenty-five years:

You are currently in possession of the most powerful anabolic environment you will ever have. Nothing you can buy will match it. The only question is whether you’re going to use it.

Most teenagers chasing peptides are doing so while sleeping six hours, eating largely processed food, drinking on weekends, training inconsistently, and skipping protein.

They are looking for a shortcut past a road they have never actually walked.

Here is the road.

Sleep — the most powerful anabolic tool you own

Eight to ten hours a night. Not seven. Teenagers genuinely need more than adults, and almost none get it.

Here is why this matters more than any injection: the large majority of your daily growth hormone is released during deep sleep, in pulses concentrated in the first few hours. Testosterone is produced predominantly during sleep. Muscle protein synthesis, tissue repair, and memory consolidation all happen at night.

A teenager sleeping six hours has voluntarily shut down the most powerful growth pathway in their own body — and then goes online to buy a compound that tries to imitate it.

You cannot supplement your way out of that. You can only sleep your way into it.

Consistent bed and wake times, including weekends. Dark, cool room. Phone out of the bedroom — and I mean physically out, not face-down, because the mere presence of it measurably reduces sleep quality and attention.

Fix this first. It is free, it is the highest-leverage thing available to you, and nothing else on this list works as well without it.

Eat like you’re building something, because you are

Protein at every meal. Roughly 1.6 to 2.2 grams per kilogram of body weight daily for someone training hard. Distribute it — about 30-40 grams per meal, because muscle protein synthesis responds to the per-meal dose, not just the daily total.

Eggs, meat, fish, dairy, legumes. Real food first.

Eat enough total calories. This is the single most common reason teenagers fail to build muscle. You cannot construct tissue from a deficit. If you are training hard and not growing, the answer is almost always that you are not eating enough — not that you need a peptide.

Cut the ultra-processed food and added sugar. Not because of purity culture, but because of what they actually do: drive insulin resistance, inflammation, and poor recovery, and displace the nutrients you need to build tissue. A diet built on packaged food and sugary drinks is a diet that fights your training.

Eat real food. Vegetables, fruit, whole grains, quality protein, olive oil, nuts. Boring, unglamorous, and it is what every well-built body is actually made of.

Train properly — and progressively

Resistance training three to five times weekly, built around compound movements: squat, hinge, push, pull, carry.

Progressive overload is the entire mechanism. Add weight or reps over time. Keep a log. The log is what turns intention into progress.

And understand the timeline honestly: meaningful muscle development takes years, not months. Everyone you follow who looks impressive has either been training consistently for a very long time, is using something, or both. The compressed timelines you see online are largely fiction, and comparing your six months to someone’s six years is how good training programs get abandoned.

No alcohol. No drugs. No vaping.

Alcohol suppresses testosterone, blunts muscle protein synthesis, wrecks sleep architecture, and impairs recovery for days after a single episode of heavy drinking.

The adolescent brain is undergoing its most significant remodeling since infancy. Alcohol, cannabis, and nicotine all interfere with that process, and the earlier the exposure, the more consequential it is.

Nicotine and vaping constrict blood vessels, impair recovery, and create dependency in a developing brain faster than in an adult one.

If you are serious about building your body, this is not a moral position. It is the single easiest performance decision available to you.

Manage stress, and move outside

Chronic stress elevates cortisol, which directly opposes muscle building and impairs recovery. Time outdoors, daily movement, real friendships, and something you do that isn’t optimization.

The honest promise

Do those five things consistently — sleep, protein, real food, progressive training, and no substances — for two years, and you will have a better body than any peptide protocol would have given you.

You will also have it permanently, without hormonal disruption, without infection risk, and without an unanswerable question about what you did to yourself at fifteen.

The basics are not the slow path. They are the only path. Everything else is decoration on top of them — and for a teenager, dangerous decoration.

PART SIX: FOR PARENTS — WHAT TO LOOK FOR AND WHAT TO SAY

Warning signs

Packages arriving that your teen intercepts, particularly small padded envelopes.

Small glass vials, syringes, alcohol swabs, or bacteriostatic water — that last one is worth searching for specifically, because there is no innocent explanation for it in a teenager’s room.

Sharps or needle caps in the trash.

Unusually rapid physical change, or dramatic swings in mood, appetite, or sleep.

New injection marks, particularly on the abdomen, shoulders, or thighs.

Sudden expertise in vocabulary — dosing, reconstitution, “stacking,” “cycling,” “research chemicals,” specific compound names.

Unexplained spending or requests for gift cards and crypto, which is how a great deal of this is purchased.

And a heavy focus on “looksmaxxing,” body optimization content, or fitness influencers in what they consume.

How to have the conversation

Do not lead with punishment. If your teenager believes disclosure means losing their phone and their gym membership, they will simply get better at hiding it — and the danger here is contamination and dosing, both of which get worse in secret.

Lead with curiosity. “I’ve been reading about the peptide stuff kids are buying online. What are you seeing about it?” You will learn more in five minutes of that than in an hour of interrogation.

Take the underlying motivation seriously. They are not doing this because they are reckless. They are doing this because they want to look a certain way, because that pressure is genuinely intense, and because their entire feed is telling them that everyone else has an edge. Dismissing that will end the conversation instantly.

Use the physiology, not the morality. “Your growth plates are still open and you already have more growth hormone than you’ll ever have again” lands considerably better with a sixteen-year-old than “drugs are bad.” Teenagers respond to being treated as intelligent.

And use the specific fear that actually works: the risk of ending up shorter. For a teenager chasing physical development, permanent height loss is the consequence that registers.

Involve a physician early if you suspect use. Not for punishment — for baseline bloodwork, for an honest conversation with someone who is not their parent, and because if there has been injection with unregulated product, infection risk needs to be assessed.

And examine what’s driving it. Body dysmorphia, disordered eating, and appearance-related anxiety are dramatically underdiagnosed in adolescent boys specifically, because we screen girls and assume boys are fine. If the drive here is distress rather than curiosity, that deserves real attention.

THE BOTTOM LINE

Peptides may eventually have a legitimate role in adults with real medical need, under real medical supervision, once the trials exist. That is a genuine conversation and I have written about it at length.

For teenagers, the answer is not complicated.

There is no deficiency to correct. The natural systems are running at peak capacity. The long-term risks are unknown and unknowable for decades. The products are frequently contaminated. And the specific window being interfered with — growth plates, puberty, hormonal calibration, brain development — closes permanently and does not reopen.

You can take something to look bigger at fifteen and end up shorter at twenty-five.

To the teenager who read this far: you already have the most powerful anabolic environment of your entire life running right now, for free, every night while you sleep.

Sleep eight to ten hours. Eat real food and enough of it. Lift progressively for years. Stay away from alcohol and drugs. Be patient.

That is not the boring alternative to the shortcut.

That is the thing the shortcut is a bad imitation of.

Protect the years when your body is still building itself. You only get them once, and nothing you can buy will give them back.

Parents: share this with another parent. Most have no idea this is happening, and it is happening in a lot of houses. And if your teenager will read it, that may matter more than anything you say — sometimes the same information lands differently from a doctor than from a father.

This article is educational and not personalized medical advice. If you suspect a young person is using these compounds, involve a physician promptly — particularly if there is any sign of infection at an injection site, which can escalate rapidly.

Follow me on X: @afshineemrani — daily on cardiology, metabolic health, longevity, and the research most people never hear about until it is already standard of care.

Subscribe to this newsletter — completely free. No paywall. No supplement line. Nothing to sell you. Just a cardiologist writing what I would want my own children to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Join our new website: doctoremrani.com

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

Explore my books: Amazon Author Profile

During those years it damages arteries. It fills the liver with fat. It disrupts fertility. It changes how the brain regulates hunger. It elevates cancer risk. And it does all of this while your blood glucose stays perfectly normal and your physician tells you your labs look fine.

It is insulin resistance. And the reason it goes undetected is not that we lack a test.

It is that the test that finds it early is not part of your annual physical, and almost nobody orders it unless you ask by name.

I am a cardiologist, and I treat the downstream consequences of this condition every single day — the heart attacks, the strokes, the heart failure, the arterial disease. By the time these patients reach me, the process that caused their disease has typically been running for two decades.

This handbook is my attempt to move that timeline forward. What insulin resistance actually is, what it is not, how it presents in people who do not fit the picture, exactly how to get diagnosed, and the complete protocol for reversing it.

The central message is simple and I want it stated at the top:

By the time your glucose is abnormal, you are late. The window for easy reversal is the decade before that — and you can find it, if you know what to ask for.

PART ONE: WHAT INSULIN RESISTANCE ACTUALLY IS

Insulin has two primary jobs. It moves glucose out of your bloodstream and into cells for energy or storage. And it signals your liver to stop producing additional glucose.

In insulin resistance, cells stop responding properly to that signal.

And here is the crucial compensation that hides the entire disease: your pancreas responds by producing more insulin. More signal, same result. Glucose stays in the normal range.

Not because you are metabolically healthy. Because your pancreas is working progressively harder to keep you looking that way.

That compensation can hold for a decade or considerably longer. Eventually the pancreatic beta cells begin to fail, insulin production can no longer keep pace, and glucose finally rises. At that point you are diagnosed with prediabetes or type 2 diabetes.

The diagnosis marks the failure of compensation — not the beginning of the disease.

This is why I tell patients that a normal fasting glucose is one of the most misleading reassurances in medicine. It tells you the compensation is still working. It says nothing about how hard your pancreas is working to achieve it.

PART TWO: WHY YOU CAN BE HUNGRY AND GAINING WEIGHT AT THE SAME TIME

This section explains something millions of people have experienced and been blamed for, and it deserves to be understood properly.

Different tissues become insulin resistant at different rates. This is the key insight, and it changes how the whole condition makes sense.

Muscle cells become resistant relatively early. They take up less glucose, which means less fuel entering the tissue that should be burning it.

Liver cells become resistant to the signal telling them to stop producing glucose. So your liver continues dumping glucose into circulation even when there is already plenty.

Fat cells, however, often remain insulin-sensitive longer. They are still receiving the message clearly — and insulin’s message to a fat cell is store.

So the picture becomes: high circulating insulin, muscle that cannot efficiently use fuel, a liver adding glucose it should be withholding, and fat tissue enthusiastically storing everything available. Preferentially as visceral fat, packed around the organs.

And then there is the brain

Insulin also acts in the brain, where it participates in satiety signaling and supports cerebral glucose metabolism.

When the brain becomes insulin resistant, you remain hungry despite enormous quantities of insulin circulating. And brain glucose metabolism can drop, which likely contributes to the fog, the low energy, and the mood changes people describe but struggle to articulate.

There is a genuine paradox here worth naming: chronically elevated peripheral insulin can result in relatively lower effective insulin action in the brain.

What this means, and I want to be emphatic

The lived experience becomes: constantly hungry, persistently low energy, steadily gaining fat around the middle — and being told, by doctors and family and the culture, to try harder.

That is not a willpower failure. It is a signaling failure.

The signal telling you that you have eaten enough has stopped arriving. The signal telling your fat cells to store is being received perfectly.

If you have been shamed about your weight while experiencing exactly this, I want you to read that paragraph twice. You were not weak. You were fighting a hormone.

PART THREE: WHAT INSULIN RESISTANCE IS NOT

It is not the same as type 1 diabetes, which results from autoimmune destruction of insulin-producing beta cells. Entirely different disease, entirely different mechanism.

It is not simply “eating too much sugar.” Diet matters enormously, and refined carbohydrate is a major driver. But genetics, sleep, circadian disruption, chronic stress, medications, hormonal conditions, muscle mass, and inflammation all contribute substantially.

It is not always accompanied by obesity. This is one of the most consequential misconceptions in medicine.

There is a well-described phenotype — sometimes called TOFI, “thin outside, fat inside,” or metabolically obese normal weight — in which a person of entirely normal body weight carries high visceral and hepatic fat, low muscle mass, and marked insulin resistance.

These people are massively underdiagnosed, precisely because they do not look the part and therefore nobody checks.

It is not a moral or character failure. See Part Two. This is hormonal signaling, and the signaling is measurable.

And critically: it is not irreversible. For the great majority of people, substantial improvement is achievable — which is exactly why detecting it early matters so much.

One more: a high fasting insulin does not mean you have diabetes. And a normal glucose does not rule out insulin resistance. Those two facts, held together, explain most of the diagnostic failure in this field.

PART FOUR: WHAT CAUSES IT

Visceral and ectopic fat. Not fat under the skin, but fat stored around organs and inside the liver and muscle. This is why waist circumference is more informative than weight, and why a lean person can be metabolically ill.

Physical inactivity and low muscle mass. Skeletal muscle is your largest glucose disposal organ. Less muscle means fewer places for glucose to go and greater demand on insulin to force it there.

Chronic caloric surplus, particularly from refined carbohydrate and ultra-processed food in susceptible individuals.

Sleep deprivation and circadian disruption. This one is more dramatic than people expect — even a few nights of restricted sleep measurably worsens insulin sensitivity in previously healthy people. Shift work is a genuine metabolic risk factor.

Chronic stress. Cortisol directly opposes insulin action. This is physiology, not weakness.

Genetics and family history. Real, substantial, and not your fault.

Medications — glucocorticoids most notably, along with certain antipsychotics and some antiretrovirals.

Aging and menopause. The menopausal transition drives genuine shifts in insulin sensitivity and fat distribution, and it begins in perimenopause — years before periods stop.

Inflammation and oxidative stress, which function as both cause and consequence, creating a self-reinforcing loop.

In women specifically: polycystic ovary syndrome, a history of gestational diabetes, and in some cases hormonal contraceptives.

PART FIVE: HOW IT PRESENTS — THE SIGNS PEOPLE MISS

Early insulin resistance can be entirely silent. But there are signals, and most of them get attributed to something else.

Fatigue after meals — the post-lunch crash that feels like you need to lie down. This is one of the earliest and most commonly dismissed signs.

Carbohydrate cravings that feel compulsive rather than casual.

Weight gain concentrated around the midsection, or an inability to lose it despite genuine, sustained effort.

Acanthosis nigricans — dark, velvety patches of skin on the neck, in the armpits, or in the groin. This finding is nearly diagnostic of insulin resistance, and it is constantly mistaken for dirt or poor hygiene, including by patients themselves. It is neither. It is a hormonal skin change.

Skin tags, often clustered in the same regions.

High triglycerides, low HDL, and rising blood pressure — the metabolic syndrome cluster, which frequently appears on a standard panel before anyone connects the dots.

Fatty liver, often discovered incidentally on an ultrasound ordered for something else entirely.

PART SIX: YOUNG WOMEN — THE MOST MISSED GROUP IN MEDICINE

In young women, insulin resistance very frequently presents as polycystic ovary syndrome — and it is often the underlying driver rather than an incidental finding.

How it shows up:

Irregular or absent menstrual periods. Anovulation and difficulty conceiving. Hyperandrogenism — acne, unwanted facial or body hair, scalp hair thinning in a male pattern. Central weight gain or difficulty losing weight. Substantially elevated risk of gestational diabetes and later type 2 diabetes. And mood symptoms — anxiety, depression — that the metabolic disruption genuinely worsens rather than merely accompanies.

And here is what gets missed constantly

Lean women with PCOS can have marked insulin resistance.

Driven by genetics and by ovarian and adrenal androgen excess rather than by excess adipose tissue.

If you are slim with irregular cycles, unexplained acne, or hair changes — you can be significantly insulin resistant, and almost nobody will check, because you do not fit the mental image the clinician is carrying.

Other presentations worth flagging in women: a history of gestational diabetes (which is insulin resistance revealing itself under metabolic load, and carries substantial future risk), rapid weight gain after starting certain medications, and sleep apnea — which is underdiagnosed in women because we present differently.

If you have PCOS, irregular cycles, or a gestational diabetes history — ask for a fasting insulin. Regardless of your weight. Especially if you are planning pregnancy.

PART SEVEN: HOW TO ACTUALLY GET DIAGNOSED

No single perfect test exists in routine practice. But the tests below, taken together, will find this years before a standard panel does.

Fasting insulin — the test that changes everything

Target: under 5 μIU/mL. Ideally 3-4.

This is the single test that identifies insulin resistance ten to fifteen years before glucose moves. Laboratory reference ranges commonly extend to 25 or higher — because those ranges describe a population that is largely metabolically unwell, not a target for health.

Almost nobody orders this. You will likely have to ask for it by name.

A fasting insulin of 12 with a normal glucose is not reassuring. It is a pancreas working overtime, and it is exactly the finding you want to catch.

HOMA-IR

Calculated from fasting insulin and fasting glucose:

(fasting glucose in mg/dL × fasting insulin in μIU/mL) ÷ 405

Target under 1.0. Above 2.5 generally indicates meaningful insulin resistance. You can calculate this yourself the moment you have both values.

Triglyceride-to-HDL ratio

Free. Calculated from any standard lipid panel you already have.

Under 2 is good. Under 1 is excellent. Above 3 is a red flag regardless of what your total cholesterol says. It is one of the best available proxies for insulin resistance and for the presence of small dense LDL particles.

The supporting panel

HbA1c — optimal under 5.4%, not merely under the 5.7% prediabetes threshold. Note that A1c can read falsely low with rapid red cell turnover and falsely high in iron deficiency, so interpret it alongside the rest.

Fasting glucose — under 90 is optimal. The standard cutoff of 100 is late.

Waist circumference — more informative than weight or BMI for metabolic risk.

ALT and AST — for fatty liver. And note the reinterpretation: standard ranges extending to 40 were derived from populations full of undiagnosed fatty liver. Optimal ALT is likely under 25 in men and under 20 in women.

Full lipid panel and blood pressure.

More informative, if available

An oral glucose tolerance test with insulin levels measured — not just glucose. This reveals the compensation your fasting numbers may still be hiding, and it is considerably more sensitive.

Continuous glucose monitoring can reveal post-meal excursion patterns invisible on fasting labs.

The hyperinsulinemic-euglycemic clamp remains the research gold standard but is not a clinical test.

PART EIGHT: THE PROTOCOL — WHAT ACTUALLY REVERSES IT

Lifestyle is not the consolation prize here. For insulin resistance, it is the most powerful intervention that exists, and it works faster than most people expect.

1. Build muscle — the highest-leverage intervention

Skeletal muscle is your largest glucose disposal tissue. More muscle means more capacity to absorb glucose and less demand on insulin to force it there.

Resistance training two to four times weekly. Build sessions around compound movements: squat pattern, hinge pattern, push, pull, and carry. Progressive overload is the entire point — add weight or reps over time, and keep a log.

This becomes more important with age and through the menopausal transition, not less. Muscle mass is metabolic insurance.

2. Walk after meals

Ten to fifteen minutes after eating. This blunts post-meal glucose excursions more effectively than almost any free intervention available, because contracting muscle can take up glucose through a pathway that does not require insulin at all.

If you do one thing from this entire handbook, do this one.

3. Cut ultra-processed food and refined carbohydrate

This is the single highest-yield dietary change for most people. Sugar-sweetened beverages first — they deliver a rapid glucose and insulin load with essentially zero satiety.

4. Protein and fiber at every meal

Fiber: 25-38 grams daily. Most patients get half that. Legumes are the single best source, followed by vegetables, whole grains, nuts, and seeds.

Protein at every meal stabilizes blood sugar, preserves muscle mass, and provides genuine satiety.

5. Stop grazing

Constant snacking keeps insulin elevated all day, and the whole problem is chronically elevated insulin.

Two or three defined meals, without grazing in between, gives your body actual low-insulin windows. This is often more impactful than changing what you eat.

6. Front-load your calories

Insulin sensitivity peaks in the morning and declines through the day. The identical meal produces meaningfully different metabolic consequences at 8am versus 8pm.

Larger breakfast and lunch. Lighter dinner. Stop eating three hours before bed.

A 10-12 hour overnight fast is achievable for nearly everyone and captures most of the benefit of time-restricted eating without extremes.

7. Sleep — and get tested for apnea

Seven to nine hours, with consistent timing. Short sleep worsens insulin resistance within days.

If you snore, wake unrefreshed, or your partner notices you stop breathing — get a sleep study. Untreated sleep apnea drives insulin resistance, hypertension, and inflammation simultaneously, and treating it can improve every other number in this handbook.

8. Manage chronic stress

Cortisol directly antagonizes insulin. Slow breathing, meditation, time outdoors, movement, and — the part nobody says — actually addressing the structural sources of stress in your life.

9. Target visceral fat specifically

Even modest visceral fat loss markedly improves insulin sensitivity. Focus on fat loss while preserving or building muscle, rather than scale weight alone. Watch your waist.

10. Correct the deficiencies

Magnesium, vitamin D, and omega-3 when genuinely low. Limit alcohol. Do not smoke.

How fast does it work?

Improvements can appear within weeks to months. Different tissues recover at different rates — liver and muscle often respond relatively quickly. Retest at eight to twelve weeks after making changes.

PART NINE: MEDICATIONS

Lifestyle remains foundational. Medications are added when lifestyle alone is insufficient, or when risk warrants faster intervention.

Metformin. First-line for many. Reduces hepatic glucose output and modestly improves peripheral insulin sensitivity. Widely used in PCOS and prediabetes, inexpensive, with decades of safety data. Note that long-term use warrants B12 monitoring.

GLP-1 receptor agonists (semaglutide, tirzepatide). Powerful for appetite regulation, weight loss, and glycemic control, improving insulin resistance both through fat loss and through additional mechanisms. Now with substantial cardiovascular and kidney outcome data. If you use these, the protein and resistance training in Part Eight become non-negotiable — otherwise a meaningful fraction of the weight you lose will be muscle.

SGLT2 inhibitors. Helpful for glucose with strong cardiac and kidney protection, plus modest weight loss.

Pioglitazone. Directly improves insulin sensitivity — genuinely, at the receptor level — with side effect considerations including weight gain, fluid retention, and bone risk.

For PCOS specifically: combined oral contraceptives, anti-androgens, and fertility treatments are frequently layered on top of metabolic therapy. Choice depends on age, fertility goals, and comorbidities.

All of these require medical supervision and individualization.

PART TEN: WHY THIS MATTERS — THE COMPLICATIONS

Untreated, insulin resistance progresses to prediabetes and type 2 diabetes. But long before that, hyperinsulinemia itself causes damage.

Cardiovascular disease. This is why a cardiologist writes about it. Insulin resistance drives small dense LDL particles, high triglycerides, low HDL, hypertension, endothelial dysfunction, and systemic inflammation. It is upstream of the disease that kills more people than anything else.

Fatty liver disease, progressing to steatohepatitis, fibrosis, and in some cases cirrhosis.

Certain cancers — endometrial, breast, colorectal among them — partly through insulin and IGF-1 growth signaling. Insulin is a growth hormone, and chronically elevated growth signaling has consequences.

Cognitive decline and elevated dementia risk, through brain insulin resistance and cerebral glucose hypometabolism.

Reproductive dysfunction and pregnancy complications.

Chronic inflammation, kidney disease risk, and worsening sleep apnea — each of which feeds back into the others.

And the mental health burden, which is real and rarely counted: the energy, the mood, the self-image, and the accumulated experience of being told it is your fault.

PART ELEVEN: THE THINGS PEOPLE MOST OFTEN MISS

Insulin resistance can exist with a completely normal weight and a completely normal fasting glucose. Both facts together are why it goes undiagnosed for a decade.

Hyperinsulinemia has independent effects beyond glucose — growth promotion, sodium retention and blood pressure elevation, and appetite dysregulation. The high insulin is itself doing harm, not merely marking it.

Recovery is tissue-specific and non-linear. Do not expect everything to improve in lockstep.

Young women with PCOS or irregular cycles should be evaluated even if slim.

Muscle is medicine — and it becomes more important, not less, with age and hormonal change.

Early intervention can delay or prevent progression for many years, and in many cases indefinitely.

And monitor more than glucose. Look at triglycerides, waist, liver enzymes, blood pressure, symptoms, and — when useful — insulin itself.

THE BOTTOM LINE

Here is what I want every person reading this to carry away.

You can have normal glucose, a normal HbA1c, a normal weight, and a physician telling you everything looks fine — while being a decade into a disease nobody has named yet.

The compensation that keeps your glucose normal is the same thing that hides the disease. And when that compensation finally fails, you receive a diagnosis for a process that has already been damaging your arteries, your liver, and your brain for years.

The test that finds it early costs almost nothing. Ask for fasting insulin by name, because you will almost certainly have to.

If it comes back elevated, understand precisely what you have been handed. Not a diagnosis — a decade of warning. A window during which this remains largely reversible, using tools that are free and available to you starting tomorrow.

Build muscle. Walk after meals. Cut the ultra-processed food. Fix your sleep. Stop grazing. Retest in three months.

Most people never get that warning. They get the diagnosis instead, twelve years later, when the easy window has closed.

Go get your number.

If this was useful, share it — particularly with anyone who has been told their labs are fine while feeling exhausted, hungry, and blamed for it. And with any young woman with PCOS or irregular cycles who has never had a fasting insulin drawn.

This handbook is educational and not personalized medical advice. Diagnosis and treatment require a qualified clinician who can interpret your labs in context, rule out other conditions, and tailor a plan — particularly for women planning pregnancy or with PCOS. If you have symptoms or risk factors, seek evaluation rather than self-diagnosing.

Follow me on X: @afshineemrani — daily on cardiology, metabolic health, longevity, and the research most people never hear about until it is already standard of care.

Subscribe to this newsletter — completely free. No paywall. No supplement line. Nothing to sell you. Just a cardiologist writing what I would want my own family to know, including the inconvenient parts and the parts my profession gets wrong.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Join our new website: doctoremrani.com

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

Explore my books: Amazon Author Profile

Los Angeles Heart Specialists 18370 Burbank Blvd., Suite #401, Tarzana, CA 91356 818-996-4100

That framing is now badly out of date, and it is costing people who could genuinely benefit — because they hear “weight loss,” decide the conversation isn’t about them, and never learn that this class reduces heart attacks, strokes, kidney failure, and possibly dementia.

Here is where we actually are.

What began as a single hormone has become a family — single, dual, and triple receptor agonists. The newest of them just produced 28.3% average weight loss in a Phase 3 trial. That is approaching bariatric surgery territory with a weekly injection.

And yet there is a serious problem almost nobody is warning patients about, one that can leave you frailer at a lower weight than you started.

This manual covers all of it: the complete map of the drug family, every documented benefit across organ systems, exactly who benefits most, who should avoid these entirely, the nutritional and training protocol that determines whether your weight loss builds you or hollows you out, and the practical details your prescriber may never mention.

I wrote a book on this subject because I got tired of the conversation being dominated by either uncritical enthusiasm or reflexive dismissal. This article is the current, condensed version of what I believe.

PART ONE: THE FAMILY TREE

Single agonists — the foundation

Semaglutide, liraglutide, dulaglutide. These activate the GLP-1 receptor, producing four effects simultaneously: slowed gastric emptying, enhanced glucose-dependent insulin release, suppressed glucagon secretion, and quieted appetite signaling in the hypothalamus.

Typical weight loss: 10-15%.

Why “glucose-dependent” matters more than people realize: insulin is released only when blood glucose is actually elevated. This is why these drugs rarely cause hypoglycemia on their own — a genuine safety advantage over older diabetes medications like sulfonylureas, which push insulin regardless of need.

Dual agonists — two receptors, synergistic effects

GLP-1 + GIP (tirzepatide). GIP adds insulin sensitivity and improved lipid handling on top of the GLP-1 effects. Weight loss up to approximately 21%.

GLP-1 + glucagon (survodutide, mazdutide). This combination is conceptually different and worth understanding. The glucagon arm raises energy expenditure and drives hepatic fat oxidation. You are not merely eating less — you are burning more. This makes them particularly powerful for liver disease.

GLP-1 + amylin (CagriSema). Amylin recruits a separate satiety pathway plus gastric effects, adding to the GLP-1 mechanism.

Triple agonists

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously: appetite suppression, insulin sensitization, and increased energy expenditure all at once. This is the agent producing bariatric-adjacent results.

PART TWO: WHAT JUST CHANGED

Retatrutide’s Phase 3 data is in

TRIUMPH-1: 28.3% average weight loss at 80 weeks on the 12mg dose, with up to 30.3% at 104 weeks in the higher-BMI extension.

That is the largest reduction ever reported in a Phase 3 obesity trial.

It remains investigational. Filing is expected in the first quarter of 2027, with approval realistically not before 2027-2028. Anyone selling you retatrutide today is selling you something from a gray market, not a pharmacy.

The oral era arrived

Oral semaglutide 25mg was approved in December 2025 — roughly 16.6% weight loss in the OASIS 4 trial.

Then orforglipron was approved on April 1, 2026 — the first small-molecule oral GLP-1 receptor agonist. It can be taken any time of day, with no food or water restrictions, unlike the peptide-based orals that require careful fasting protocols.

Its approximately 12% weight loss trails the injectables. But focusing on that misses the point entirely: fewer than one in ten eligible patients currently take any GLP-1. The barrier has never been efficacy. It has been injections, cost, and supply.

Being a small molecule rather than a peptide, orforglipron is also far easier to manufacture at scale — which matters enormously for supply and eventually for price.

And an honest disappointment

CagriSema failed non-inferiority against tirzepatide in February — 20.2% versus 23.6% at 84 weeks in a head-to-head trial.

I include this deliberately. The field does not only produce wins, and you should be suspicious of anyone who only tells you about the successes.

PART THREE: THE CARDIOVASCULAR DATA

This is my field, and this is why I stopped calling them weight loss drugs.

SELECT

17,604 people with obesity and established cardiovascular disease, without diabetes. Semaglutide cut major adverse cardiovascular events — cardiovascular death, nonfatal heart attack, nonfatal stroke — by 20%.

Here is the detail that changed my thinking: roughly a third of that benefit appeared independent of weight loss, and cardiac protection began emerging before significant weight came off.

That tells you these drugs are doing something directly to the vasculature and to inflammation — not simply helping by shrinking people.

Across the class

13-20% reduction in major adverse cardiovascular events, with specific reductions in myocardial infarction, stroke including fatal stroke, and heart failure hospitalization. Benefits extend to peripheral arterial disease.

Heart failure with preserved ejection fraction

This deserves its own paragraph, because HFpEF is a brutal condition for which we have had almost nothing to offer.

Roughly 40% relative risk reduction in heart failure hospitalization in some analyses. And in the SUMMIT trial, tirzepatide cut cardiovascular death or worsening heart failure by 38% in patients with HFpEF and obesity.

For many of these patients, this is the first genuinely effective therapy anyone has been able to offer them.

The mechanisms

Lower hs-CRP and systemic inflammation. Lower blood pressure. Lower triglycerides. Effects on atherosclerotic plaque. And direct receptor activity in cardiac and vascular tissue — GLP-1 receptors exist in the heart and blood vessels, not merely the gut and brain.

PART FOUR: KIDNEY, LIVER, AND SLEEP

Kidney

The FLOW trial: 24% fewer serious kidney events and 20% lower all-cause mortality.

Reduced albuminuria, slower eGFR decline, and delayed progression to kidney failure — with or without diabetes.

For anyone with chronic kidney disease, this is a major development. We have had very few interventions that meaningfully alter that trajectory.

Liver

Dramatic reductions in liver fat — 60-86% with the dual and triple agonists — plus enzyme normalization and genuine fibrosis resolution signals. The ESSENCE trial resolved MASH inflammation in approximately 63% of patients.

The glucagon-containing agents excel here, which points toward something important: a patient with heavy liver fat may be better matched to a glucagon-inclusive drug than to a pure GLP-1.

That is what personalized incretin therapy will look like — matching the receptor profile to the phenotype.

Sleep apnea

Tirzepatide is now FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

SURMOUNT-OSA demonstrated large reductions in apnea-hypopnea index, hypoxic burden, blood pressure, and inflammatory markers — improving sleep independent of, or additive to, CPAP.

This one matters enormously downstream. Untreated sleep apnea drives hypertension, atrial fibrillation, insulin resistance, and low testosterone. Treating it improves nearly everything else.

PART FIVE: THE SIGNALS WE ARE STILL CHASING

I want to label these clearly as promising rather than established.

Brain

Observational data and meta-analyses link GLP-1 use to roughly 30% lower dementia and Alzheimer’s risk in diabetes cohorts, with improved cognitive scores in mild cognitive impairment and early signals in Parkinson’s disease.

Preclinical work shows reduced neuroinflammation, amyloid, and tau pathology. Dedicated randomized trials using oral semaglutide are running now, and their results will matter a great deal.

Cancer

Propensity-matched analyses of obesity-related cancers show 38-50% lower likelihood of progression from stage I-III to metastatic disease among GLP-1 users, with roughly 30% signals for lower breast cancer incidence and recurrence. Higher tumor GLP-1 receptor expression correlates with better outcomes.

These are associative and require confirmatory trials. I will not overstate them. But the proposed mechanism — reduced inflammation, lower insulin and IGF-1 signaling, less visceral fat — is biologically coherent.

Also documented

Lower alcohol consumption and cravings, with reduced substance use disorder risk across categories. Fewer venous thromboembolic events. Osteoarthritis symptom relief. PCOS improvement. Better wound healing. And measurable reductions in sick days, physician visits, and emergency department utilization.

PART SIX: WHO SHOULD TAKE THESE

Let me be direct about the strongest candidates.

Type 2 diabetes, particularly with established cardiovascular disease or chronic kidney disease. Here these are arguably first-line beyond metformin, and the outcome data is robust.

Obesity with established cardiovascular disease. The SELECT population. If this is you and you are not having this conversation with your cardiologist, you should be.

Obesity with heart failure, particularly HFpEF. The SUMMIT data is genuinely important.

Chronic kidney disease with albuminuria. FLOW.

MASLD or MASH — especially with a glucagon-containing agent when available.

Obesity with moderate-to-severe obstructive sleep apnea — tirzepatide now has a specific indication.

Metabolic syndrome with a strong family history of premature cardiovascular disease.

And people who have genuinely tried. I want to say this plainly, because the moralizing around obesity remains ugly: if you have made serious, sustained attempts at lifestyle change and your biology fought you, that is not a character failure. Obesity is a chronic disease with powerful hormonal defenses of body weight. Using an effective medication for a chronic disease is not cheating. Nobody calls a statin cheating.

PART SEVEN: WHO SHOULD AVOID THEM — OR PROCEED WITH REAL CAUTION

This section is the one most articles skip, and it matters as much as everything above.

Absolute contraindications

Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This is a boxed warning based on rodent thyroid C-cell tumor findings. The human relevance remains uncertain, but the contraindication is firm.

Known hypersensitivity to the agent or its components.

Pregnancy. These should be discontinued well before a planned pregnancy — typically at least two months before, given the long half-lives — and they are not for use while breastfeeding. Important and underdiscussed: improved fertility with weight loss and restored ovulation means unintended pregnancies happen. If you are of reproductive age, discuss contraception explicitly. Oral contraceptive absorption may also be affected by delayed gastric emptying.

Serious cautions requiring individual judgment

History of pancreatitis. Not an absolute contraindication in most guidance, but it warrants genuine caution and shared decision-making. If you have had confirmed GLP-1-associated pancreatitis, do not restart.

Gastroparesis or severe gastrointestinal motility disorders. These drugs slow gastric emptying by design. Adding that to a stomach that already empties poorly is a bad combination.

Active gallbladder disease or a history of gallstones. See the gallbladder section below — risk is genuinely elevated.

Proliferative diabetic retinopathy. Rapid glucose lowering can transiently worsen retinopathy. This requires ophthalmology involvement and careful monitoring, not avoidance necessarily — but it must be addressed before starting.

Active eating disorder, or a significant history of one. This is the one I feel most strongly about and see handled most poorly. A powerful appetite suppressant in someone with anorexia nervosa, bulimia, or a restrictive eating history can be genuinely dangerous. Screen for this honestly. If you have that history, tell your prescriber even if you would rather not.

Significant frailty or sarcopenia already present, particularly in older adults. See Part Eight — you can make a frail person frailer.

Severe renal or hepatic impairment. Requires dose adjustment and specialist input.

Planned surgery or procedures requiring anesthesia. Delayed gastric emptying raises aspiration risk. Tell your surgeon and anesthesiologist you are on a GLP-1 — guidance on holding doses before procedures exists and continues to evolve. This is a real safety issue, not a formality.

Type 1 diabetes — not an approved indication, and use requires specialist management.

And a category of caution nobody discusses

If you cannot commit to adequate protein and resistance training, particularly if you are over 60 or postmenopausal, seriously reconsider the timing.

I am not saying you cannot have the medication. I am saying the drug plus neglect produces a specific bad outcome — rapid loss of muscle and bone — and you should know that before you start rather than discover it on a DEXA scan two years later.

PART EIGHT: THE WARNING ALMOST NOBODY GIVES PATIENTS

Rapid weight loss of any kind — including with these drugs — costs you lean tissue.

If unmitigated, 20-40% of total weight lost can be lean mass.

And bone follows muscle. Studies show measurable declines in hip and spine bone mineral density — around 2% in some 52-week data — with increased bone resorption markers and observational signals of higher osteoporosis diagnosis rates in long-term users.

Fracture data is genuinely mixed. Some analyses show neutrality or even protection in diabetes cohorts. I will not overstate this. But the risk concentrates exactly where you would expect: older adults, postmenopausal women, and anyone with low baseline bone density.

The mechanism is largely secondary: reduced calorie and nutrient intake including calcium, vitamin D, and protein; loss of the muscle that mechanically loads bone; and hormonal shifts during rapid catabolism. Direct drug effects on bone appear neutral to mildly negative.

You can lose 25% of your body weight and end up frailer than when you started.

That is not theoretical. I see it. And sarcopenia and low bone density are what determine whether you spend your last decade in your own home or in a facility.

The drug is half the treatment. Here is the other half.

PART NINE: THE PROTEIN PROTOCOL

Target 1.2-1.6 grams per kilogram of body weight daily. Higher end if you are over 60 or losing rapidly. For a 90kg person, that is roughly 110-145 grams daily.

Distribute it: approximately 0.3-0.4 g/kg per meal — about 30-40 grams per sitting. Muscle protein synthesis responds to the per-meal dose, not merely the daily total. One large protein dinner does not substitute for three adequate meals.

Leucine is the trigger. Aim for roughly 2.5-3 grams per meal — approximately what is contained in 30 grams of high-quality protein. Whey, eggs, dairy, meat, and fish are leucine-rich. Plant sources generally require larger portions to reach the same threshold.

Higher protein intake correlates directly with less lean mass loss on these drugs. This is the single most important variable you control.

And here is why it is genuinely hard: the medication suppresses appetite, which is the entire point of taking it. You must eat with intention rather than waiting for hunger to arrive.

Practical approach: protein first, every meal, before anything else on the plate. A protein shake is legitimate nutrition in this context, not a shortcut — when appetite is suppressed, liquid calories that are nutrient-dense are a tool, not a compromise.

PART TEN: THE TRAINING PROTOCOL

Protein supplies the raw material. Resistance training is the signal that tells your body to keep the muscle. Without the signal, the protein has nowhere useful to go.

Two to four sessions weekly. Non-negotiable.

Build every session around compound movements that load the hips, spine, and legs — the sites that lose bone first:

Squat pattern (back squat, goblet squat, leg press, split squat) · Hinge pattern (deadlift, Romanian deadlift, hip thrust) · Push (overhead press, bench press, push-up) · Pull (row, pull-up, lat pulldown) · Carry (farmer’s walk, suitcase carry)

Rep ranges: 5-8 with a genuinely challenging load for strength and bone. 8-12 for muscle hypertrophy. Do some of each. The final two or three reps should be difficult.

Progressive overload is the entire point. Add weight, reps, or sets over time. Keep a log — the log is what makes progression actually happen rather than remaining an intention.

And add impact if your joints allow: 10-20 jumps, hops, or heel drops daily. Rope skipping counts.

Bone responds to exactly two signals: heavy loading and impact. Walking does not build bone density. It is excellent for other reasons — cardiovascular health, glucose control, mood — but it will not preserve your skeleton during rapid weight loss.

Medication plus training preserves bone mineral density substantially better than medication alone. This is the difference between losing fat and losing yourself.

PART ELEVEN: MICRONUTRIENTS AND MONITORING

Appetite suppression means you are eating less of everything, not merely fewer calories.

Calcium 1,000-1,200mg daily, food first, spread across the day for better absorption.

Vitamin D to a blood level of 40-60 ng/mL — take D3 with K2, with a fat-containing meal.

Magnesium — required to activate vitamin D and supports the bone matrix.

Plus iron, zinc, and B12 — check these, particularly if you were already marginal before starting.

What to monitor

Baseline DEXA if you are postmenopausal, over 60, of low body weight, or have a family history of osteoporosis. Repeat it during treatment.

Track strength, not just the scale. Grip strength. What you can lift. How fast you walk. If those numbers are falling while your weight falls, something is wrong with how you are losing.

Body composition beats scale weight, always. A 15% loss that is nearly all fat is a better clinical outcome than a 25% loss that took your quadriceps with it.

PART TWELVE: THREE THINGS YOUR PRESCRIBER MAY NOT MENTION

Gallbladder risk, and how to reduce it

These drugs slow gallbladder emptying through reduced cholecystokinin signaling, and rapid weight loss supersaturates bile with cholesterol. The result is meaningfully elevated gallstone risk.

Practical mitigation that almost nobody explains:

Do not do prolonged fasting windows on these drugs. Regular smaller meals stimulate gallbladder contraction and emptying. Long fasts allow bile to sit and concentrate — exactly the wrong thing when your gallbladder is already sluggish.

Do not eliminate dietary fat entirely. Fat is the primary trigger for gallbladder contraction. Very low-fat eating during rapid weight loss is a recipe for sludge and stones.

Know the warning signs: right upper quadrant pain especially after fatty meals, pale stools, dark urine, yellowing of the eyes or skin, persistent nausea.

Asymptomatic enzyme elevations are not pancreatitis

Mild rises in amylase and lipase are expected pharmacology on these drugs. The positive predictive value of an isolated asymptomatic elevation for actual clinical pancreatitis is under 1%.

Routine surveillance enzyme testing in asymptomatic patients is not recommended by FDA prescribing information, the ADA Standards of Care, or major gastroenterology and endocrine societies.

Yet patients are being taken off effective, life-extending therapy over trivial laboratory changes. I see it constantly, and it is a genuine harm.

Real pancreatitis means severe, persistent upper abdominal pain, often radiating to the back, typically with nausea and vomiting. That is a stop-immediately-and-evaluate situation. A number on a routine panel in someone who feels fine is not.

Plan for maintenance before you start

Weight regain after discontinuation is substantial in the trial data. This is chronic disease therapy, not a course of antibiotics.

Discuss the long-term plan before you begin — including what happens if insurance coverage changes, if supply tightens, or if you need to stop for surgery. Knowing the plan in advance prevents the panic and the rapid regain that follow an abrupt stop.

PART THIRTEEN: WHERE THIS IS GOING

By 2027-2028, retatrutide and the next wave should push average weight loss toward 28-30%, with substantially stronger multi-organ outcome data.

Oral small molecules will democratize access — the barrier was never efficacy, it was needles, cost, and supply.

Monthly dosing is in Phase 3. Indications will keep expanding into MASH, additional heart failure phenotypes, osteoarthritis, and possibly the first neurodegenerative approvals if the ongoing trials succeed.

And critically: combinations pairing incretins with muscle-preserving agents — activin receptor antagonists such as bimagrumab — are already in trials, targeting precisely the lean mass problem described above.

The future is matching drug to phenotype. Heavy liver fat to a glucagon-inclusive agent. Sleep apnea to tirzepatide. Adherence difficulty to an oral. Sarcopenia risk to a combination that protects muscle.

THE BOTTOM LINE

Here is how I think about this class now.

These have stopped being weight-loss medicine and become foundational cardiometabolic therapy — arguably the most important development in my field since statins.

Fewer heart attacks. Fewer strokes. Less kidney failure. Better sleep. Resolved liver inflammation. Possibly less dementia and slower cancer progression.

But the drug is only half the treatment.

Eat the protein. Lift the weights. Watch body composition, not the scale. Get the DEXA. Keep the muscle.

And know honestly whether you belong in the group who should take these — or in the group who should wait, or avoid them entirely. That conversation is worth having properly, with a physician who will discuss both columns.

Otherwise you will get the number you wanted, and lose the body you needed to carry it.

If you want the complete version

I wrote a book on this, because the public conversation kept collapsing into either uncritical enthusiasm or reflexive dismissal, and patients deserved better than both.

The GLP-1 Breakthrough: A Cardiologist’s Secrets for a Healthier Life — the full clinical picture, the protocols, the safety details, and how to have this conversation with your doctor.

If this article was useful, the book is where the rest of it lives.

Share this with someone starting a GLP-1 who has not been told about the muscle and bone piece. That conversation may matter more than any other one they have about this medication.

This article is educational and not personalized medical advice. Do not start, stop, or change any medication without your own physician. If you develop severe abdominal pain on a GLP-1 receptor agonist, seek medical attention immediately.

Follow me on X: @afshineemrani — where I post daily on cardiology, metabolic health, longevity, and the research most people never hear about until it is already standard of care.

Subscribe to this newsletter — completely free, no paywall, nothing to sell you. Just a cardiologist writing what I would want my own family to know, including the inconvenient parts and the parts my profession gets wrong.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Join our new website: doctoremrani.com

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

Explore my books: Amazon Author Profile